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Principal aims of the thesis 
hERG as a molecular and pharmacological target? 
 
Leukemia represents a type of cancer very heterogeneous in the modality of 
development and also in the capability to respond to various treatments. In fact 
notwithstanding the remarkable progress attained in these last decades, a considerable 
percentage of patients still fail in response to standard drug treatments (chemotherapy or 
radiotherapy).  
In fact many patient cases have an unfavorable outcome due to unpredictable 
development of the pathology, non specific distribution of drug, inadequate drug 
concentrations reaching the target, intolerability and development of multi-drug 
resistance. The advent of genomic technologies allowed to develop data that address the 
molecular profile of cancer for each patient, thus laying the foundation for the 
development of a personalized therapy. The molecular profile allows to evidence 
biomarkers, including mutated and overexpressed genes, as well as genes encoding 
fusion proteins (for example bcl-abr in chronic myeloid leukemia, CML). 
Since many years, research in our laboratory underlined the importance of human ether 
a-gò-gò related gene (hERG) potassium channel activity in cancer, especially in 
leukemia. My thesis project fits on this research current in which are just demonstrated 
hERG role : 
1. in the progression thought G1 phase of the acute myeloid leukemia (AML) cell 
cycle; 
2. in migration and invasiveness from bone marrow to peripheral blood and AML 
diffusion into extramedullary organs; 
3. in chemoresistance of acute lymphoblastic leukemia cells (ALLs) induce by the 
presence of bone marrow mesenchymal cells (MSCs). 
For these reasons, hERG could be considered as a possible target in antineoplastic 
therapy and hERG inhibitors as a possible anticancer drugs. However the use of hERG 
blockers in clinical therapies is limited by the side effects induced in the patients. In fact 
Kv11.1 channels contribute to shape of action potential repolarization in ventricular 
heart myocytes. After depolarization, during the repolarization phase, they quickly 
recover from inactivation, thus transiently opening, they close again at the negative 
membrane potential. The most serious side effect induced by hERG inhibitors is caused 
by the prolongation of the cardiac repolarization and in turn in the extension of QT 
interval in the ECG. An uncontrolled QT interval lengthening can result in torsade de 
points (TdP), a ventricular arrythmia that may lead to ventricular fibrillation. 
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Our goal should be the development of new antineoplastic drugs, targeting hERG 
avoiding arrhtythmia and strengthening the positive effects of hERG inhibition, 
including reduction of leukemia invasiveness and chemoresistance induced by the 
presence of MSCs. In order to obtain these purposes we have attempted two different 
approaches: pharmacological and molecular.  
The first of these approaches is based on the study of pharmacological effects of the 
hERG blocker, clarythromicin and its combinatorial effect with a conventional 
chemoterapic cytarabine, in vitro and in vivo. In vitro the experiments are conducted on 
acute promyelocitic leukemia cell line (HL60) in suspension and in co-colture with 
MSCs. We underline the effect of clarythromicin alone and its effect combined with 
cytarabine in HL60 and also in co-colture. 
Presently, the experiments are conducted in vivo by Dr. Marika Masselli using acute 
promyleocitic leukemia cell line HL60-luc for imaging in NOD-SCID mouse. In 
particular the effect of clarytromycin alone and in combination with cytarabine has been 
studied. 
The second approach is based on the development of new lipid based vectors for RNA 
interference (RNAi) targeting hERG. RNAi is an evolutionary conserved phenomenon 
whereby small double-stranded RNA regulates gene expression. The versatility of the 
RNAi mechanism has led to its exploitation for the treatment of diseases. However, 
many physiological obstacles stand in the way of successful and efficient use of RNAi 
as therapy. One of main challenges is the design of practical delivery reagents that are 
capable of protecting siRNA in circulation, as well as safely and efficiently delivering it 
to cytoplasm of appropriate cell types in vivo. A number of nonviral carriers have been 
used for potential in vivo delivery siRNA, including cationic polymers, peptides or 
liposomes and lipid-like materials that form complexes with negatively charged siRNAs 
by ionic interactions. Our attention is focused on four cationic surfactants namely:         
12-3-12, 12-6-12, 12-12-12 and SH14, as possible delivery agents of siRNA. It is well 
established that cationic surfactants in aqueous solution self-assembly into micelles that 
are able to interact with the negative backbone of siRNA. Our attempt is the study of 
time-resolved complexation of siRNA and cationic surfactant micelles. This method 
allows to obtain informations not only on the aggregate internal structure and size but 
also of the timing necessary to obtain complexes with size useful for biological use. 
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First Part 
 
Targeting hERG channels: a pharmacological 
approach through macrolide antibiotics 
 
Chapter 1 
 
1.1 Potassium channels 
Voltage gated-like ion channels (VGICs) constitute the third largest group of signaling 
molecules encoded by the human genome, after protein kinases and G protein. 1 Within 
VGICs, K+ channel genes represent the most extended superfamily with 78 members.  
According to the IUPHAR classification K+ channels can be divided into four structural 
types on the basis of their mode of activation and the number of transmembrane (TM) 
segments present in each channel subunits: 
1. inwardly rectifying 2-TM K+ channel (Kir); 
2. two-pore, 4 TM (K2P); 
3. calcium activated, 6 or 7 TM (KCa); 
4. voltage-gated, 6 TM (Kv) 
 
1.1.1 Inwardly rectifying K+ channel 
Inwardly rectifying K+ (Kir)2 currents are first identified in skeletal muscle.3 They show 
greater flow of K+ into the cell, rather than out of it. Kir channels have been found in a 
wide variety of cells: cardiac myocytes4, neurons5, blood cells6, osteoclasts7, endothelial 
cells8, glial cells9, epithelial cells10 and oocytes11. 
In 1993 the ATP-dependent Kir channel ROMK1/Kir1.112 and the ATP-dependent Kir 
channel IRK1/Kir2.113 were isolated, respectively from the outer medulla of rat kidney 
and from a mouse macrophage cell line respectively, and then characterized. Their 
primary structure is characterized by two transmembrane domains (TM1 and TM2), 
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linked by an extracellular pore-forming region (H5) and cytoplasmic amino (NH2)- and 
carboxy (COOH)- terminal domains. The H5 region permits the selective transport of 
K+ ions thanks the signature sequence T-X-G-Y(F)-G which characterized only K+ 
channel. The lack of the S4 voltage sensor region makes this channel insensible to 
membrane voltage and active at all membrane potential (Figure 1.1, panel A). 
Inwardly rectifying channel are made up by four subunits each in a tetrameric complex. 
Actually 15 Kir subunit genes have been identified and classified into seven subfamilies 
(Kir1.x to Kir7.x).  
1) classical Kir channels (Kir2.x); 
2) G-protein gated Kir channel (Kir3.x); 
3) ATP-sensitive K+ channels (Kir6.x); 
4) K+-transport channel (Kir1.x, Kir4.x, Kir5.x, Kir7.x) 
The simplicity and strong homology of the basic Kir channel subunit allow for both 
homomeric and heteromeric combinations to form functional Kir channels. Heteromeric 
assemblies generally occur within members of the same subfamily, for example, Kir 2.1 
can associate with any one of other Kir2.x subfamily members. An exception is 
represented by Kir4.1 that aggregates with Kir5.1. 
Many factors regulate pore opening kinetics and ion flux, such as ions, polyamines, 
nucleotides, lipids and a variety of intracellular proteins. Inward rectification of K+ flux 
through Kir channels result from the interaction between two intracellular substances, 
Mg2+and polyamines.14,15 
Other blockers most commonly used for Kir channels are Ba+ and Cs+, also 
tetraethylammonium (TEA) and 4-aminopyridine (4-AP).16,17 
 
1.1.2 Two-Pore Domain Potassium Channels 
The family of two domain potassium (K2P)18 channels includes fourteen members 
encoded by different genes. These members are divided into six subfamilies: TWIK, 
TREK, TASK, THILK, TALK and TRESK on the basis of sequence similarities and 
functional resemblance. However the members of different subfamilies show relatively 
low sequence similarity.19 The 2 pore domain potassium channels are characterized by 
the same general structure. Each subunit contains two pore -forming regions arranged in 
tandem (P1 and P2) and four transmembrane segments (TM1-TM4) (Figure 1.1, panel 
B). Accordingly, K2P subunits dimerize to constitute the functional selectivity filter 
containing four pore loop domains, a structure common to all known potassium 
channels. The hypothesis that K2P channels give rise to background K+ current, is well 
established. This current follows the Goldman-Hodgkin-Katz current equation20 and 
regulates the resting membrane potential, as well as excitability of many kinds of cells. 
These channels influence cell membrane potential and excitability and thereby modulate 
a variety of processes including hormone secretion, proliferation, and central nervous 
system (CNS) functions.  
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They play a central role not only in physiological conditions, but also in pathological 
processes, like cancer. The involvement of K2P channel in tumor biology has recently 
discovered. The first evidence was demonstrated in breast cancer21 where 
K2P9.1(TASK3) is overexpressed. Other indications were provided in prostate cancer 22 
and neuronal tumors.23 In this field the development of new drugs to regulate K2P 
channel activity has become urgent. Recently, ML308 has been identified as a novel 
inhibitor of the potassium channel, subfamily K, member 9 (KCNK9).24 Other inhibitor 
of K2P members are cations like Ba2+ or chloroform. 
 
1.1.3 Calcium –activated potassium channel 
The family of calcium-activated potassium channels25,26 includes eight different 
members divided in two groups: the former, exhibiting large unitary conductance and 
gated by the cooperative action of membrane depolarization and internal concentration 
of Ca2+ , is termed BKCa; the latter displaying small conductance and gated exclusively 
by internal concentration of Ca2+ is called SKCa.27  
BKCa channels are implicated in the regulation of smooth muscle tone,28 in the 
microbial killing by leukocytes29 and in the modulation of hormone and 
neurotransmitter release.30 They are abundantly expressed in the most regions of the 
brain where BKCa channels contribute to repolarization of action potentials, mediate the 
fast phase of depolarization31, shape the dendritic Ca2+ spikes32 and influence the release 
of neurotransmitters. SKCa channels cover a wide range of activity from controlling 
uterine contractility33, vascular tone34, modulation of hormone secretion35, control of 
cell volume in red blood cells36, activation of microglia and lymphocytes37,38, to 
regulation of excitability39, synaptic signal transduction40. 
The BKCa channel core is a tetrameric assembly of α-subunits (BKα). Their primary 
structure comprises seven transmembrane domains (S0-S6) in between the short 
extracellular NH2 terminus and the large intracellular COOH terminus. In turn the 
intracellular domain contains (i) four hydrophobic segments (S7-S10), (ii) two 
regulating conductance of K+ (RCK) domains and (iii) a stretch of aspartate residues 
that are known as “Ca2+ bowl”. Tertiary folding of these residues constitute the binding 
site for Ca2+,  whose occupancy is one of the two source of channel opening. The other 
modality of channel gating is membrane depolarization by movement of the voltage-
sensing segment S2-4.41 (Figure 1.1, panel C) Although tetramers of BKα are 
functional, the majority of BKCa in the plasma membrane are associated with auxiliary 
β-subunits (BKβ) having a modulatory effect on gating, pharmacology, as well as on 
trafficking. 
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Figure 1.1: Molecular structure of potassium channels: α-subunit structure forming rectifying 
potassium channel (A); one of the two domain making K2P family (B); two different structures of 
the KCa family (C) and molecular structure of one subunit of Kv family and the functional tetramer 
(D).42 
 
 
The SKCa channel is a tetrameric assembly of α-subunits (SKα). Their primary structure 
includes six transmembrane domain but lacks the voltage-sensing S4 segments. SKα 
gating is driven by a change in the intracellular Ca2+ concentration, through the binding 
of the C-terminal region with calmodulin.43 
The most common BKCa blockers are TEA, charybdotoxin, a neurotoxin from the 
scorpion and quindine, an antiarrhythmic agent while SKCa are commonly blocked by 
apamina, a neurotoxin found in apitoxin, and by the tamapina toxin product from Indian 
Red Scorpion.25 
 
1.1.4 Voltage gated potassium channel (Kv) 
Kv channels represent the largest gene family in the K+ channel group, they are encoded 
by 40 genes which are divided into 12 subfamilies including hERG which is the main 
focus of this thesis. 
Kv channels are formed by four α-subunits arranged around a central pore as 
homotetramers and heterotetramers. Each subunit contains six transmembrane α-helical 
segments (S1-S6) and a membrane entering P-loop which contributes to form the ion 
conduction pore. S4 helix contains four positively charged arginine residues, as a 
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voltage sensor domain and determines the opening of the pore, pulling on the S4-S5 
linker.44-46 (Figure 1.1, panel D) 
Because of K+ concentration gradient across the plasma membrane, the opening of Kv 
channel results in an efflux of positive charge, which can serve to repolarize and 
hyperpolarize the membrane. In excitable cells such as neurons or cardiac myocytes, Kv 
channels, often expressed together with voltage-gated Na+ and/or voltage-gated Ca2+ are 
involved in the repolarization after action potential firing.  
Therefore Kv channel play an important role in Ca2+ signaling, volume regulation, 
secretion, proliferation and migration in both excitable or non-excitable cells.47,-49 
K+ efflux trough Kv channels is involved in the counterbalancing of Ca2+ influx in order 
to maintain an inward-rectifier Ca2+ current, necessary for cellular activation and 
migration. It is well established that Kv channels take part to large supramolecular 
complexes. The behavior of these complexes can be influenced by the channel in the 
absence of ion flow.  
Kv channel activity is modulated by several molecules which could be divided in three 
categories: metal ions, organic small molecules (molecular weight of about 200-500 Da) 
and venom peptides (molecular weight 3-6 kDa).50 These substances interfere with Kv 
channel function by blocking the ion-conducting pore from the external or internal side, 
or modifying channel gating binding the voltage sensor domain or auxiliary domain. For 
example peptide toxins bind either to the outer vestibule or the voltage sensor of Kv 
channels. Another examples are small agents, like tetrabutylammonium, d-tubocurarine 
and verapamil that block Kv channels occluding the inner pore or inserting their 
ammonium group into the ion permeation pathway. Correolide interact through its 
lipophilic domain, with S6 helix while with its polar acetyl group chelates K+; in this 
way this nucleophilic molecules is able to block Kv.51 
Another mechanism to modulate Kv channel with β-subunits is the disruption of the 
interaction between α- and β- subunits.52 
 
1.2 hERG (human ether a-gò-gò related gene) K+ channels. 
The human ether a-gò-gò related gene (hERG) encodes pore forming subunit of a 
delayed rectifier voltage-gated K+ (VGK) channel. This channel is variously referred to 
as IKr, hERG, Kv11. 1 or KCHN2. HERG is a member of one of the three subfamilies of 
the ether a-go-go family of VGK channels. Within the family of Kv11.x, there are three 
members, Kv11.1 (hERG), Kv11.2 (hERG2), and Kv11.3 (hERG3), but Kv11.1 is 
prevalently discussed in this thesis. 
The family name ether a gò-gò was given by Kaplan and Trout in 1969 and was 
intended as a humorous reference to how the legs of mutant flies shake under ether 
anesthesia like the gò-gò dancers of the 1960s.53 
The human KCHN2 gene are made of ~36kb in region q36.1 on chromosome 7. (Figure 
1.2). 
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Figure 1.2: Genomic structure of KCHN2. Genome browser view of chromosome 7 q36.1. KCHN2 
is transcribed in the reverse direction. Three alternative transcription start sites and two 
alternative termination sites give rise to five transcripts. 5’UTR and 3’UTR are shown in cyan and 
coding regions in blue. 
 
 
It is transcribed in the reverse direction. Three alternative transcription start sites and 
two alternative termination sites give rise to five transcripts: KCHN2-1a, KCHN2-1b, 
KCHN2-1c (KCHN2-3.1), KCHN2-1a-USO and KCHN2-2a-USO.  
KCHN2-1a contains 15 exons and corresponds to the longer transcript. KCHN2-1b has 
a transcription start site in intron 5, resulting in a transcript missing the first five exons 
of KCHN2-1a and containing an alternative exon 5b. KCHN2-1b is identical to 
KCHN2-1a from exon 6 onwards.  
KCNH2-1c (KCNH2-3.1) has a transcription start site in intron 2. It lacks the first two 
exons and has six additional amino acids at the 5’ end of exon 3 but for the rest, it is 
identical to KCHN2-1a. In addition to the termination site in exon 15, there is another 
3’UTR end within intron 9 of the KCHN2-1a mRNA. Transcripts with this premature 
COOH-terminal truncation are called hERGUSO.  
The KCHN2-1a transcript giving rise to a 1159-amino acid protein (hERG) contains six 
transmembrane (TM) segments (S1-S6). S1-S4 contains the voltage sensor domain 
(VSD) while S5-S6 loop contribute to forming the pore domain. Each subunit presents 
large cytoplasmic NH2-terminal and COOH-terminal domains. The first one contains a 
Per-Arnt-Sim (PAS) domain that defines the ether a gò-gò subfamily of VGK channel. 
The COOH terminus contains a cyclic nucleotide binding domain (cNBD) which shows 
homology with the cNBD of CNG channels and hyperpolarization activated channel 
(HCN) (Figure 1.3). 
First Part-Chapter 1- 
 
 
9 
 
 
 
Figure 1.3: Topology and structure of Kv 1.1 chennels. Panel A shows a linear sequence of hERG-1a 
with domains color coded. Arrows indicate the transcription start sites, and dashed lines show the 
sites of exon-exon boundaries. Panels B shows the extracellular view (left) and intracellular view 
(right) of the tetrameric structure of Kv 11.1 channels. Panels C reported the topology of two 
opposing hERG-1a subunits color-coded as in A. 
 
 
The functional channel is a tetramer where S5-S6 linker of each subunit surrounds the 
central pore, controlling the K+ efflux. 
Within KCHN2 gene exon 1 encodes the 5’UTR and first residues, which play an 
important role in deactivating regulation of the channel. 
Exon 2 and exon 3 contain PAS domain. Exon 6 encodes the last portion of the 
cytoplasmic NH2 terminus and first three transmembrane domain. Exon 7 encodes the 
fourth TM segment containing the positive residues acting as the principal voltage-
sensing region within the VSD. The aminoacid bounding exon7/8 is the mostly 
conserved residues in all K+ channels (Gly648 in hERG). Exons 8-10 encode the c-
linker and cNBD domains while the remaining five exons encode the distal COOH-
terminal domain. 
 
1.2.1 hERG channel: operating mechanism. 
hERG is expressed in a multiple tissues and cell types, including neural54, smooth 
muscle55 and tumor cells56. In the central nervous system of mammals, two other hERG 
channel genes are expressed (hERG2-3) and here heteromultimeric57 channel complexes 
of all three subunits are be formed. However hERG is most highly expressed in the 
heart and disease where its function and dysfunction are best understood. 
The action potential of human ventricular myocytes can be divided into five distinct 
phases. Phase 0 is characterized by activation of inward Na+ current that triggers a rapid 
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depolarization of the membrane. Phase 1 repolarization starts and is due to the transient 
outward K+ current (Ito). This phase proceeds rapidly in few milliseconds and is 
followed by phase 2 consisting of a much slower rate of repolarization, called plateau. 
The plateau is due to maintained inward Ca2+ current and because the outward K+ 
current are slow to activate (slow delayed rectifier K+ current) or exhibit strong 
rectification (inward rectifier K+ current IK1 and rapid delayed rectifier K+ current, IKr, 
conducted by hERG channels). In phase 3 repolarization terminates the action potential 
and returns the membrane potential to its resting level (phase 4). The most important 
component of phase 3 repolarization is the rapid delayed rectifier K+ current (IKr) 
conducted by hERG channels. (Figure 1.4)58  
 
 
Figure 1.4: Simulated human ventricular action potential. a) At phase 0 an inward Na+ current 
triggers a rapid depolarization of the membrane. In phase 1 repolarization proceeds rapidly, 
followed by a slower rate of  repolarization in phase 2. The action potential ends in phase 3 and the 
membrane potential returns to the resting level during phase 4. b) Ion-channel currents involved 
during action potential. Phase 0 is mediated by activation of the inward Na+ current, INa. Activation 
of the transient outward K+ current, Ito, creates a brief and partial repolarization in phase 1. In 
phase 2 the plateau of the action potential is prolonged owing to a maintained inward current (ICa) 
conducted by L-type Ca2+ channels and because the outward K+ currents are slow to activate (slow 
delayed rectifier K+ current, IKs) or exhibit strong rectification (inward rectifier K+ current, IK1 and 
rapid delayed rectifier K+ current, IKr, conducted by hERG channels). Phase 3 repolarization is 
mediated by the outward currents IKr and IK1. The resting potential between action potentials is 
called phase 4. Modelling courtesy of F. Sachse, University of Utah. 
 
 
At negative membrane potential (about -80 mV) hERG channels are in non-conducting 
closed state. Depolarization of cell membrane to potential more positive than -60 mV 
induces channels to open and allows the outward diffusion of K+ ions in accordance 
with its electrochemical driving force. As the membrane potential is progressively 
depolarized to more positive potential, channels enter another non conductive 
configuration called inactivated state. (Figure 1.5) 
hERG gating is different from most Kv channels by two aspects. 
First, inactivation is much faster than activation, this reduces outward conductance at 
depolarized potentials and prolongs phase 2 of the action potential.  
Second recovery from inactivation is much faster than deactivation: this starts phase 3 
repolarization of the action potential.  
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Figure 1.5: Gating of Kv11.1 channels. It shows the states of  Kv11.1 channels: closed, open, or 
inactivated states. Transitions between them are voltage dependent, with the transition between the 
closed and open states being slower than transitions between open and inactivated states. 
 
 
Kv11.1 mutations cause the Long QT Syndrome (LQTS) type 2. This syndrome is 
defined by the prolongation of the QT interval measured by a body surface 
electrocardiogram (ECG) and greatly increased risk of ventricular fibrillation. The QT 
interval is the time required for ventricular repolarization during a single cardiac cycle. 
The lack of repolarization increases the risk of torsade de pointes (TdP), a unique 
cardiac arrhythmia characterized by an ECG trace that resembles a waxing and waning 
sine wave. TdP can either revert to a normal sinus rhythm or degenerate into lethal 
ventricular fibrillation.  
The most common hERG inhibitors are E4031, Way 123,398 and dofetilide. However 
Kv11.1 is blocked by many other compounds, such as antihistaminics (i.e. terfenadine), 
prokinetics (i.e. cisapride), antipsycothics (i.e. sertindole) and antibiotics (i.e. 
erythromycin). The chemical structure of these compounds confers them the capability 
to bind hERG channel pore at different points; these particularities could be exploited in 
order to reduced K+ potassium current without provoking uncontrolled QT prolongation 
and ventricular fibrillation. 
 
1.2.2 hERG channel under physiological and pathological conditions 
VGC channels in general, and Kv11.1 channels in particular, have been implicated in the 
regulation of cell-cycle. hERG channels are expressed at high levels in early embryonic 
stages of quail neural crest and are replaced by inward rectifier currents during 
development.59,60 It was found that the expression of hERG is particularly high in 
mouse embryonic heart and then downregulated during development.61 The presence of 
hERG is also evidenced in cells undergone to dedifferentiation,62 as well as in tissue 
samples from tumors where KCHN2 transcript and hERG protein expression is usually 
found to be more frequent than in the control tissue.63 This phenomenon could explain 
the fact that the differentiated cells display a membrane potential more negative than     
-60mV while non differentiated cells are usually more depolarized.64 
It was demonstrated in previous work from our group that the recorded membrane 
potentials of unsynchronized mammalian neuroblastoma cells vary cell-to-cell and these 
variations were attributed to different steady-state activation curves of Kir inward 
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rectifier currents. Therefore it was first proposed that Kir channels are a relevant target 
in the transformation process in cancer cells. Subsequently it was found that the mix of 
hERG subunits varies at different phases in the cell cycle of synchronized tumor cells. 
For example hERG-1b isoform is dominant during the S phase, while hERG-1a subunit 
during the G1 phase. These results account for a correlation between biophysical 
parameters of Kir and different phases of the cell cycle.65 
Not surprisingly, the same ion-channels that are involved in cell proliferation, are also 
implicated in the process of apoptosis. For instance cell shrinkage, that characterizes the 
early steps of apoptotic cell death, is due to K+ efflux. It is well established that 
potassium channels are involved in cytoskeleton reshaping and cell-cell interactions; 
these phenomena represent the initial step towards increased cell motility, a prerequisite 
for tumor invasion. In fact hERG has important implications for the invasiveness of 
cancers. In human colorectal cancer, it was found that hERG66 regulates invasion of 
tumor cells and it is more expressed in metastatic cancers with a bad prognosis than in 
less aggressive cancers. 67 
This trend was observed in human leukemia cases, in which patients with hERG 
positive tumors have a higher mortality than in patients with hERG negative tumors.68 
Furthermore, the interaction between K+ channel and integrin plays a pivotal role in 
cancer cell migration since integrin is involved in cell adhesion through its interaction 
with fibronectin. It was found that in leukemic cell line FLG 29.1 fibronectin increases 
hERG current through the interaction with integrin. In turn, hERG activation leads to 
increased expression of αv β3 integrins, indicating that hERG channels are involved both 
in ouside-in and inside-out signaling in these cells. 
Further experimental evidences showed that interaction of hERG channels with β1 
subunit of the integrin receptor in leukemia and neuroblastoma cells could influence 
molecular signaling, such as tyrosine kinases and GTPases.  
hERG and β1 subunit of the integrin interaction appears in proximity of caveolin-1 
indicating an involvement of lipids rafts/caveolae. It is also evident that focal adhesion 
kinase (FAK) associating with hERG becomes tyrosine phosphorylated after exposure 
of the cell to fibronectin; this effect could be blocked by Kv11.1 blockers.69 
In solid tumors, hERG channels play an important role in new vasculature development 
outpacing the lack of oxygen. This mechanism is modulated by Kv11.1 channel gating 
which is activated under hypoxic conditions. It was also discovered that in glioblastoma 
multiforme, hERG channels are overexpressed and modulated by VEGF secretion that 
is critical for neoangiogenesis.70 
 
1.3 Leukemia 
Leukemia represents a group of hematological malignancies, characterized by clonal 
expansion of hematopoietic cells with uncontrolled proliferation, decreased apoptosis 
and blocked differentiation.  
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According to the disease progression and hematopoietic lineages involved, leukemia 
can be divided into acute or chronic forms: 
• Acute leukemia, characterized by a rapid increase in the number of immature 
blood cells. Immediate treatment is required, in order to reduce the rapid 
progression and accumulation of the malignant cells, which migrate from the 
bone marrow environment to peripheral blood and spread rapidly to other organs 
of the body. Acute forms of leukemia are the most common forms of leukemia 
in children. 
• Chronic leukemia, is characterized by the excessive build up of relatively 
mature, but still abnormal white blood cells. The progression of this chronic 
leukemia is slower than the acute form and occurs especially in older people, but 
can theoretically occur in any age group. 
Traditionally, these malignancies are subdivided into: 
• lymphoblastic or lymphocytic leukemias, where cancerous cell originates from 
marrow cells that normally differentiate in lymphocytes;  
• myeloid or myelogenous leukemias, where tumor cells originate from marrow 
cells that normally form red blood cells, platelets and granulocyte (myeloid 
lineage). 
Combining these two classifications provide a total of four main categories: 
• Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in 
young children. It affects also adults older than 65 years. Common treatments 
are chemotherapy and radiotherapy. The survival rates is higher in children 
(85%) than in adults (50%). Subtypes include precursor B acute lymphoblastic 
leukemia, precursor T acute lymphoblastic leukemia, Burkitt’s leukemia and 
acute biphenotypic leukemia. 
• Chronic lymphocytic leukemia (CLL) is diffuse prevalently in adults over the 
age of 55. It sometimes affects younger adults, but almost never occurs in 
children. The five-year survival rate is 75%. It is incurable, but there are many 
effective treatments. One subtype is B-cell prolymphocitic leukemia, a more 
aggressive disease.  
• Acute myelogenous leukemia (AML) is more spread in adults than in children 
and occurs more commonly in men than in women. The five –year rate survival 
is 40% except for acute promyelocytic leukemia (APL), which is over 90%. 
Subtypes of these malignancies include APL, acute myeloblastic leukemia, and 
acute megakaryoblastic leukemia. 
• Chronic myelogenous leukemia (CML) affects prevalently adults; only a small 
percentage of children is affected. Treatments is with imatinib (Gleevenec in 
United States, Glivec in Europe) or with other drugs (i.e. dasatinib). The five-
year rate is 90% 
• Hairy cell leukemia (HCL) affect prevalently adult men (80%). It is incurable, 
but easily tractable since survival is 96%-100% at ten years. 
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• T-cell prolymphocytic leukemia (T-PLL) is a very rare and aggressive leukemia 
affecting adults; somewhat more men than women are diagnosed with these 
disease. Despite its overall rarity, it is also the most common type of mature T 
cell leukemia. It is difficult to treat, and the median survival is measured in 
months. 
• Large granular lymphocytic leukemia may involve either T-cells or NK cells, it 
is rare and indolent (not aggressive) leukemia. 
• Adult- T leukemia is caused by human T-lymphotropic virus (HTLV) that 
infects CD4+ T-cells and replicates within them. HTLV immortalizes T-cells, 
giving them the ability to proliferate abnormally. Human T cell lymphotropic 
virus type I and II (HTLV-I/II) are endemic in certain areas of the word. 
Leukemia is a treatable disease. Most treatments involve chemoterapy, medical 
radiation therapy, hormone treatments, or bone marrow transplant. The survival 
percentage depends on the type of leukemia, as well as the age of patient. Children are 
more likely to be permanently cured than adults. In 2010, globally, approximately 
281500 people died for leukemia malignancy. In 2000, 256000 persons (adults and 
children) contracted leukemia, and 209000 died for it. This represents about 3% of the 
almost seven million deaths due to cancer in that year and about 0.35% of all deaths for 
any cause. Leukemia represent the 11th most common cause of cancer-related death. 
About one third of children affected by this cancer in general suffer from acute 
lymphoblastic leukemia. This type of leukemia is the second most common form of 
cancer in infants (under the age of 12 months) and in older children. Boys are somewhat 
more likely to develop leukemia than girls.  
 
1.4 hERG role in leukemia 
Leukemia originates from an abnormal and uncontrolled proliferation of blood stem 
cells within the bone marrow environment. During tumor development, these cells 
spread from the bone marrow to blood circulation, penetrating in extramedullary organs. 
Leukemia cells persistence in peripheral blood and subsequently their migration into 
organs, are considered unfavorable prognostic factors. In fact at these stages, patient 
response to chemotherapy is consistently reduced. In this field, biological researches 
strongly pushes to understand the molecular mechanisms regulating leukemia cell 
motility and transendothelial migration.  
Research work conducted in our laboratory provides strong evidences that hERG 
channel activity is necessary for the progression of AML cells beyond the G1/S 
boundary.71 
Subsequently it has been determined the crucial role of hERG1 channels in AML cell 
migration and invasion. This mechanism are activated by the formation of molecular 
complex composed by hERG1, vascular endothelial growth factor receptor-1 (VEGFR-
1 or FLT-1) and β1 subunit of integrin receptors. FLT-1 and hERG1B are constitutively 
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associated in leukemia cells and their assembly is potentiate by the signaling activated 
by VEGF. Therefore the recruiting of β1 subunit in the complex FLT-1/hERG1B 
activates both MAPK and PI3K/Akt signaling pathways. hERG specifically inhibition 
confirm his role in FLT-1 dependent AML migration and invasion, and its presence in 
tumor confers a stronger malignancy.72 
Therefore it has been demonstrated that bone marrow mesenchymal cells (MSCs) 
induce drug resistance in leukemic cells. It has been determined that activation of 
hERG1 channel induced by the presence of MSCs, is crucial in ALL chemioresistence. 
Co-colture experiments suggest that MSCs factor (SDF-1) induces on the ALL plasma 
membrane, the expression of a signaling complex formed by hERG channels, the β1 
integrin subunit and the CXC chemokine receptor-4. The assembly of this molecular 
complex activates both the extracellular signal/related kinase 1/2 (ERK1/2) and the 
phosphoinositide 3-kinase (PI3K)/Akt prosurvival signaling pathways. Inhibition of 
hERG channel through silencing by siRNA or E4031 approaches evidence the reduction 
of ALL chemioresistance induced by the presence of MSCs.73 
Recently it was found that hERG1B is up-regulated in comparison to hERG1A in ALL 
blasts, either B or T lineage.74 As previously described hERG1 blockers can overcome 
chemoresistance both in vitro and leukemia mouse models. However hERG1 inhibitors 
could have a side effect on myocardial tissue. hERG1B overexpression in ALL patients 
may have clinical importance since hERG1B is expressed at low levels in human heart. 
For this reason, hERG1B targeting could be an approach for antileukemic therapy, 
avoiding adverse cardiac effect. 
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Chapter 2 
 
2.1 Clarithromycin: current use in medicine 
Clarithromycin is a macrolide antibiotic of second generation, used for the treatment of 
respiratory tract infections, sexually transmitted diseases and infections caused by 
Helycobacter pylori and Mycobacterium avium complex.  
The first macrolide discovered is erythromycin that has been used since the early 1950s 
for the treatment of respiratory tract, skin and soft tissue infections in susceptible 
organisms, especially in patients who are allergic to penicillin. In order to improve 
pharmacodynamics, pharmacokinetics and tolerability, advanced macrolide antibiotics 
are synthetized by altering the erythromycin base. One of these new agents is 
clarithromycin, also known as Biaxin.  
Clarithromycin or 6-methylerithromicin consists of a macrocyclic 14-memebered 
lactone ring with two sugar moieties: a neutral sugar, cladinose, and an amino sugar, 
desosamine. In comparison to erythromycin, clarithromycin shows a methoxy group in 
C-6 instead of hydroxil group. This substitution creates a more acid-stable antimicrobial 
compound and prevents degradation into an hemiketal intermediate, which results in 
improved oral bioavailability and reduced gastrointestinal intolerance.75 
 
 
 
Figure 2.1: Chemical structure of clarythromicin (left) and some of its commercial forms (right). 
 
 
 
 
 
Lactone ring  
(14 CH
2
-) 
 
desosamine 
cladinose 
First Part-Chapter 2- 
 
 
17 
 
These drug is available as immediate-release tablets (250 or 500 mg), extended-release 
tablets (500mg), and granules for oral suspension (125 or 250 mg/5mL) (Figure 2.1). 
Clarithromycin is antibacterials drug and inhibits RNA-dependent protein synthesis. It 
binds the domain V in 23S ribosomal RNA of the 50s subunit of bacterial ribosome. 
Substantially, this macrolide blocks the translocation of aminoacyl transfer-RNA and 
polypeptide synthesis.76,77 
This drug is metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzymes 
into the active 14-hydroxy form and six additional products. Clarithromycin has a short 
half-life; however its metabolite, 14-hydroxy clarithromycin is nearly twice more active 
than clarithromycin against certain bacteria.78,79 
30% - 40% of an oral dose of clarytromicyn is excreted in the urine either unchanged or 
as the active 14-hydroxy metabolite. The remainder is excreted into the bile. In patients 
with moderate and severe hepatic impairment, these dose should be reduced since 
clarythromycin is less metabolized into 14-hydroxy form which results in decreased 
peak plasma concentrations of the metabolite and increased renal excretion of 
unchanged clarithromycin.80,81 
Clarithromycin is particularly effective against gram-negative bacteria.79 Clarithromycin 
may be used to attenuate cardiac transplantation rejection via matrix metalloproteinase 
suppression.82 Clarithromycin has been used to study inflammatory markers in chronic 
obstructive pulmonary disease (COPD).83 It is used to study bacterial protein synthesis 
and peptide translation. It is effectively used for the treatment of the most frequently 
isolated bacterial causes of pharyngities, otitis media and sinutis. Various trials have 
demonstrated the efficacy of clarythromycin for treatment of lower respiratory tract 
infections, including acute brochitis, acute exacerbation of chronic brochitis (AECB), 
and common-acquired pneumonia.84 It is also used as an antibiotic against Helicobacter 
pylori –associated peptic ulcer diseases, ulcer recurrence. Finally, it has been shown to 
be effective in preventing and treating disseminated MAC disease in HIV-infected 
patients. 
 
2.2 Clarithromycin: mechanism of action 
2.2.1 Clarithromycin: possible antineoplastic drug? 
Clarithromycin is known to act not only as an antibiotics but also as a growth inhibitor 
of certain cancer cells. Treatments based on this drug are beneficial for unresectable 
non-small lung cancer patients and can increase the median survival of patients with 
advanced disease.85 The effect of clarithromycin and its combination with carboplatin 
and cyclophosphamide cause a significant decrease in the death rate in F-344 rats 
inoculated with 13762 mammary adenocarcinoma cells.86 
Therefore clarithromycin is well demonstrated as a potent inhibitor of tumor-induced 
angiogenesis. This effect is investigated in vivo using a mouse dorsal air sac model. The 
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inhibitory effect increased with the dose and 100mg/kg of clarithromycin administered 
intraperitoneally twice a day reduced the area of dense capillary network to about 30% 
that of the control.87  
Presently patients affected by newly diagnosed multiple myeloma are treated with low-
dose dexamethasone and lenalidomide with or without clarythromicin. Gay et al. 
demonstrated that survival percentage were significantly higher for the group treated 
with clarithromycin.88-90 
Actually there are active studies of clarithromycin in patients. These include a phase II 
trial of single agent-clarithromycin in advanced stage indolent limphoma91 or in 
combination with lenalidomide and dexamethasone in treating patients who have 
undergone stem cell transplant for multiple myeloma.92 
Recently it has been demonstrated that clarithromycin inhibits autophagy. There are 
substantial evidences that the process of autophagy plays a key role in cancer 
development. In fact autophagy has been considered an adaptive response to starvation 
induced by stress, allowing cell survival in growth factor deprived environments. 
Inhibition of the early stage induces classical apoptosis, whereas inhibition of late stage 
autophagy results in the accumulation of autophagic vacuoles, followed by apoptosis. 
Inhibition of autophagy reduce tumor cell survival and increase the sensibility to 
chemotherapy.93 
Nakamura et al. demonstrated that clarithromycin induces the inhibition of autophagy at 
late stage causing a significant induction of vacuoles in human myeloma cell lines.94 
In turn clarithromycin restores the sensibility to chemoterapy through the autophagy 
inhibition in chronic myeloid leukemia. It is well established that tyrosine kinase 
inhibitors (TKIs) have revolutionized the treatment of CML since they block Bcr-Abl 
kinase. Recently, many studies have demonstrated that TKI like imatinib or dasatinib 
induce chemoresistance due to mutation on Bcr-Abl kinase domain or by inducing 
autophagy. Carella et al. describe a series of four patients with advanced CML whose 
disease was not adequately controlled by TKIs. They demonstrated that clarithromycin 
potentiates TKIs treatment restoring the sensitivity. Three of these patients during the 
treatments stopped clarithromycin and in all cases CML disease advance after 
clarithromycin discontinuation. When the macrolide is introduced again in the 
treatment, two of the three patients had improvement in disease burden. These are 
preliminary studies but they allow to underline the importance of clarithromycin in 
cancer treatment.95 
The effect of clarithromycin is also evidenced on the K562 (CML cell line), where it 
increases the sensibility to dasantinib (TKI of second generation). In fact clarithromycin 
inhibits autophagy in a similar way to the late stage autophagy inhibitor ubiquinone. 
This effect is demonstrated by an increase in LC3-II protein levels and a concomitant 
increase in cellular vacuole formation. In conclusion, these studies demonstrate that 
autophagy may play a role in the resistance of CML cells to dasatinib therapy and 
treatment with clarithromycin restore the sensibility to the chemoterapy.96 
Clarithromycin studies on CML are preliminary but they have important clinical 
implications. The restoring sensitivity to imatinib should not be very important after the 
First Part-Chapter 2- 
 
 
19 
 
discovery of TKIs of second generation, such as dasatinib, nilotinib, bosutinib and/or 
ponatinib. In turn, there are instances where even the second generation TKIs are not so 
efficient, but in the presence of clarithromicyn their effects can be restored. 
 
2.2.2 Reduction of potassium current in hERG potassium channel  
Clarithromycin is a drug commercially used as antibiotics. Recently its pharmacological 
effect on hERG channel has been demonstrated. 
At the beginning, results obtained from previous in vitro patch clamp studies indicate 
that clarithromycin blocks the human IKr in CHO (Chinese Hamster Ovary) cell line 
with relatively low efficacy (IC50= 0.75 mM, Hill1 slope=1.7).97 
In 2000, Stanat et al. obtained encouraging evidences that clarithromycin reduces hERG 
current on HEK293 stably transfected with hERG. These authors demonstrate that 
clarithromycin reduced hERG-encoded potassium current in a concentration dependent 
manner, higher drug concentrations produce both an increasing inhibition of the evoked 
current and an induction of a time dependent block during a depolarizing step. 
Clarithromycin reduces the amplitude of potassium current after depolarization and 
during hyperpolarization, until -40 mV. (Figure 2.2, panel B). Figure 2.2 panel C 
shows the sigmoidal curves in which increasing macrolide concentration induces a 
progressive reduction of the hERG potassium tail current. 
 
 
 
Figure 2.2: Pulse protocol where 500msec step depolarization to +10mV is used to activate the 
hERG current, followed by a 500msec step to -40mV to invoke a tail current (cycle length 10sec, -
80mV holding potential) (A); superimposed currents recorded from one cell under control 
conditions and after steady state effect was achieved in the presence of 63µM and 125 µM 
clarithromycin (B). Sigmoidal curve obtains from non linear fitting on the experimental data. 
 
 
The IC50 value for Clarithromycin which corresponds to the concentration producing 
50% of K+ current reduction, is 45.7±1.1 µM. Their experiments suggest that under 
condition similar to those occurring in vivo, clarithromycin can produce a significant 
inhibitory effect on the human IKr  at clinically relevant plasma concentrations. 
A 
B 
C 
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The effect of clarithromycin is also studied in FLG 29.1 (ALL) cell line where hERG 
are expressed endogenously. (Figure 2.3) 
 
 
Figure 2.3: hERG potassium current recorded in FLG 29.1 before and after the treatment with 
Clarithromycin (350 µM). 
 
 
Patch clamp experiments allow to establish that this antibiotic strongly reduced hERG 
potassium channel. The trend obtained from these pharmacological experiments is 
similar to that observed for HEK 293 stably transfected with hERG. In turn, 
clarithromycin determines a progressive reduction of K+ current and experimental data 
fitted with Hill1 curve allow to obtain an IC50 value equal to 34±9.6 µM. 
These experimental evidences are extremely encouraging to use clarithromycin as a 
potential hERG blocker. Indeed it is well established that hERG reduction in cancer 
enhances the decrease of invasiveness and migration of leukemic cells, but at the same 
time the major side effect of hERG inhibition is ventricular arrhythmia that could cause 
patient death. At present, the proarrhythmogenic effect of clarithromycin, on the human 
heart, has not been documented. Therefore this drug is designed for practical use in 
human patients, not only as an antibiotic but also as a coadjuvant of chemotherapy in 
chronic myeloid leukemia. In this study we demonstrate its effect in acute promyelocitic  
leukemia in vitro (HL60 cell lines) and subsequently in vivo. In vitro we study the effect 
of clarithromycin and also its capability to reduce chemoresistance due to the presence 
of MSCs, through its pharmacological effect on hERG channel. 
In vivo experiments carried out by Dott.ssa Marika Masselli, allow to study the effect of 
clarithromycin alone and in combination with cytarabine. 
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Chapter 3 
 
3.1 In vitro experiments 
One of the main purposes of this thesis is the study of new antineoplastic drugs, 
targeting hERG in vitro. As discussed in the previous chapter the drug selected for this 
work is clarithromycin, a macrolide antibiotic which inhibits hERG potassium current. 
Our aim is testing this drug alone and in combination with cytarabine to investigate if 
clarithromycin can increase the sensitivity of leukemia cells toward this chemotherapic 
drug. Previous works demonstrate the positive effect of clarithromycin on K562 cells 
and on patients affected by CML.95,96 Therefore we attempt to study its effect on the 
promyelocitic acute leukemia cell line HL60, where hERG is abundantly expressed.72 
 
3.2 Materials  
3.2.1 Drug used in the treatment 
Clarithromycin used in our experiments was purchased by Sigma-Aldrich. The 
empirical formula is C38H69NO13 with molecular weight 747.95 g/mol; the powder is 
solubilized in Dimethylsulfide (DMSO, Sigma-Aldrich). 
Cytarabine used in the treatments was purchased by Sigma-Aldrich. The empirical 
formula C9H13N3O5 with molecular weight 243.22g/mol, the powder is solubilized in 
sterile water. 
 
3.2.2 Cell cultures 
HL60 cells (promyelocitic cell line) were cultured in RPMI with 10% fetal bovine 
serum (FBS, HyClone) in flasks (Corning) of 25mm maintained at 37°C, in humified 
atmosphere with 5% of CO2. Medium renewal was performed every 2 - 3 days. For 
cryopreservation, HL60s are stored in fetal bovine serum (90%) and DMSO (10%) in 
liquid nitrogen. 
 
Human bone marrow-derived MSCs, immortalized by telomerase reverse transcriptase 
transduction98, were maintained in RPMI 1640 medium supplemented with 2mM/L 
glutamine, 10% FBS (HyClone), 10-6 M hydrocortisone (Sigma-Aldrich), 100U/mL 
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penicillin, and 100 µg/mL streptomycin. These line were obtained from professor Dario 
Campana, (Department of Oncology and Pathology, St. Jude Children’s research 
hospital, Memphis, USA). 
MSCs were usually maintained in flasks (Corning) of 25mm, at 37°C, in air with 5% of 
CO2. Medium renewal was carried out every 2 – 3 days. For cryopreservation, MSCs 
were stored in fetal bovine serum (90%) and DMSO (10%) in liquid nitrogen. 
 
3.3 Methods 
3.3.1 Cell treatment 
In order to investigate the effect of clarithromycin alone and in combination with  
cytarabine, the experiments were conducted on HL60 in suspension and in co-colture. 
One day before treatment, fibronectin (1µg/well) was distributed on the bottom of 96 
well plates (Costar, Corning), where MSCs were seeded till 90% confluence. After 24 
hours, the medium of MSCs was removed and adherent cells were washed 7 times with 
AIM-V tissue culture medium (Invitrogen). The leukemic cells previously starved in 
medium without serum were centrifuged and resuspended in AIM-V medium. 10-5 
leukemic cells in 100uL were placed in each well with or without MSC layer. 
Subsequently 100 µL of AIM-V medium containing appropriate concentrations of 
clarithromycin, cytarabine (or their combination), were added to the cells. 
Cultures were maintained 48 hours at 37°C, 5% CO2 and 90% humidity, prior to flow 
cytometry assays. (Figure 3.1).  
 
3.3.2 Flow cytometry assay 
After drug treatment, leukemic cells were separated from the MSCs and processed for 
apoptosis analysis. Annexin-V- FLUOS staining kit (Roche) was used to recognize 
apoptotic cells from necrotic cells through different dyes: Annexin-V fluorescein and 
Propidium Iodide (PI). The first one is a Ca2+-dependent phospholipid-binding protein 
with high affinity for phosphatidylserine (PS) that translocate from the inner part of the 
plasma membrane to the outer layer, in the early stages of apoptosis. In turn, PI is a 
fluorescent dye that binds double-stranded DNA when cell membranes are 
compromised, remaining excluded from viable cells. 
Leukemic cells were washed twice with phosphate buffered saline solution (PBS) and 
centrifuged at 200 g for 5 min. After this, the pellet was resuspended in 100uL of 
labeling solution containing Annexin V fluorescein and PI. Samples were incubated 10-
15 min at room temperature and analyzed with FACSanto flow cytometer (Becton 
Dickinson) using 488nm excitation and 515 nm bandpass filter for fluorescein detection 
and a filter > 600 nm for PI detection. 
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Figure 3.1: Protocol used for in vitro experiments. 
 
 
3.3.3 IC50_Dose-effect curve 
The half maximal lethal dose (LD50) is a measure of the lethality of a substance. This 
parameter indicates the quantity of a given drug or other substance (inhibitor) needed to 
induce 50% of cell death. LD50 also represents the concentration of a drug required for 
inducing 50% of necrotic or apoptotic cells in vitro.  
The LD50 value is determined by analyzing dose-effect curve and fitting the measured 
response of a system at increasing concentration of the drug. Normally the curve, used 
to fit the experimental data has a sigmoidal shape. Here, we chose non-linear fitting 
curve (NLFit, Hill1) and using Origin 6 software we determined the dose that caused 
the apoptosis of 50% of leukemic cells.  
 
3.3.4 Chou-Talay method and its application in CalcuSyn 
Drug combination is widely used to treat the most dreadful disease, such as cancer. The 
main purpose is to obtain synergistic therapeutic effect, dose and toxicity reduction, 
while minimizing or delaying induction of drug resistance.99 Synergism in 
pharmacology is the term applied to the phenomena exhibiting by the combination of 
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two or more drugs in which pharmacodynamics effect produced by the mixture is not a 
simple addition of the effects produced by the two or more individual components. 
More simply, synergism is more than an additive effect and antagonism is less than an 
additive effect.100 In order to study the combination existing between two or more 
drugs, Chou and Talay elaborated a method.101 based on the median-effect equation 
where the dose of the drug is correlated with its effect as indicated below: 
 

 = 



 
 
where  is the dose of the drug,  is the median-effect dose signifying the potency,	 
is the fraction affected by the dose,  is the fraction unaffected,  = 1 −  and the 
exponent  indicate the shape of the dose-effect curve. The median-effect equation for 
a single drug can be extended to multiple drugs.102 On the basis of these equations, 
Chou and Talay introduced the term combination index (CI) for quantification of 
synergism and antagonism: 
 
 = ()() +	
()
() 
 
where CI<1, =1, >1 indicate synergism, additive effect, and antagonism. In the 
denomination, () is for  “alone” that inhibits a systems x%, and () is for 	 
“alone” that inhibits a system x%. In the numerators, () + () “in combination” 
also inhibit %.103 
The application of this method was greatly facilitated by the development of a specific 
software104, “CalsuSyn” allowing to study the combinatorial effect between two or more 
drugs. We used this software in order to investigate the combinatorial effect of 
clarithromycin and cytarabine on the HL60 cell line in suspension and in the presence of 
MSCs. 
 
3.4 Results and discussion 
The pharmacological effect of the hERG blocker was determined for clarithromycin and 
its combinatorial effects with a conventional chemioterapic cytarabine, on HL60 in 
suspension and in co-colture. These experiments allowed to clarify the role of hERG 
potassium channel in leukemia chemioresistance induced by the presence of bone 
marrow microenvironment. 
In previous experiments, HL60 were treated with increasing concentration of 
clarithromicin in two conditions: (i) suspension and (ii) co-colture with MSCs. Non-
linear fitting allowed to obtain the LD50 values of clarithromycin for HL60 shown in 
Table 3.1.  
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Clarithromycin 
Cellular line Suspension MSCs 
 
% upon LD50 % upon LD50 
HL60 50±2 37±5 28±2 67±5 
 
Table 3.1: LD50 of clarithromycin for HL60 in suspension and in co-colture with MSCs. 
 
 
The LD50 value for HL60 in suspension is 37 ±5 µM while for those in co-colture is      
67 ±5 µM. As we expected LD50 value for HL60 in co-colture is higher than in 
suspension. This meant that MSCs prevent the effect of clarithromycin, protecting them 
from the antibiotic. As expected, the bone marrow microenvironment protected 
leukemia cells from clarithromycin effects. 
In the second set of experiments HL60 were exposed to clarythromicin with or without 
cytarabine, both in suspension and on MSCs. The dose used in these experiments 
corresponded to the LD50 of each drug, i.e. 37µM for clarithromycin and 45nM for 
cytarabine.(Figure 3.2). 
Overall, the effect of each drug decreased in cultures containing MSCs, as it is reported 
in literature. In fact the percentage of apoptotic cells after clarithromycin treatment, was 
28% for HL60 in co-colture and 50% in suspension. The same effect was also obtained 
after exposure with cytarabine, since the % of apoptotic cells for HL60 was 50% in 
suspension and 20% in co-colture. This showed that the addition of clarithromycin LD50 
dose to cytarabine, essentially abrogated the protective effect of MSCs, potentiating the 
pro-apoptotic effect of chemotherapy. 
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Figure 3.2: Effect of different drugs on HL60 in suspension or co-colture MSCs. Cells were treated 
with cytarabine and clarithromycin in concentration corresponding to their LD50: i.e. 67µM and 
37nM respectively. 
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Introducing LD50 values obtained from the single drug alone and from their combination 
in Calcusyn software it was possible to evaluate if the two drugs combination  is 
synergic (CI<1), additive (CI=1) or antagonism (CI>1). As we could see in Table 3.2 
the effect of cytarabine in addition to clarithromycin is synergic on HL60 in co-colture. 
The effect of hERG blocker prevent the chemoprotective effect of bone marrow 
microenviroment restoring the sentivity to cytarabine. 
 
  clarithromycin+cytarabine 
Cellular line Suspension MSCs  p 
HL60 >1 0.657 0.009 
 
Table 3.2: CI value obtained from the treatment with cytarabine and clarithromycin in HL60 cell 
line in suspension and in MSCs. 
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Chapter 4 
 
4.1 In vivo experiments 
The encouraging data obtained from in vitro experiments led to in vivo experiments on 
Severe Combined Immunodeficiency Disease (SCID) mouse, injected with HL60 cells 
tagged with luciferase. These experiments were performed by Dott.ssa Marika Masselli 
and allowed to study the effect of clarithromycin alone or in combination with 
cytarabine. 
 
4.2 Materials 
4.2.1 Drugs used in the treatment 
In in vivo experiments we used MACLADIN® (Clarithromycin) that is resuspended in 
sterile water. 
In turn, Cytarabine, produced by Hospira, was kindly provided by Dott. Rigacci Luigi 
(Unità Funzionale di Ematologia, Azienda Ospedaliera di Careggi). 
 
4.2.2 Cell cultures 
HL60 cell lines were stably transfected with pGL4.51[luc2/CMV/Neo] (Figure 4.1) 
plasmid (Promega, Cat. #E1320) encoding the luciferase reporter gene luc2 (Pothinus 
pyralis), which has been codon-optimized for mammalian expression. This vector is 
also engineered with fewer consensus regulatory sequences for reduced backgrounds 
and decreased risk of anomalous transcription. It presents the following features: 
• luc2 reporter gene for expression in mammalian cells; 
• CMV promoter for high translational expression; 
• SV40 late poly(A) signal sequence positioned downstream of luc2 to provide 
efficient transcription termination and mRNA polyadenilation;  
• binding region for RV primer 3 and RV primer 4; 
• synthetic poly(A) signal/transcription start site;  
• synthetic Neomycin-resistance gene for mammalian cell selection of the 
plasmid; 
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• plasmid replication origin; 
• Ampicillin resistance gene for bacterial selection in vector amplification. 
 
Figure 4.1: pGL4.51[luc2/CMV/Neo] plasmid 
 
 
This vector is supplied in 10mM Tris-HCl (pH 7.4), 1 mM EDTA.105 
 
HL60-luc2 cell line were stably transfected with pGL4.51[luc2/CMV/Neo] by Marika 
Masselli. They were cultured in RPMI 1640 (Euroclone) with 10% fetal bovine serum 
(FBS, HyClone) and neomycin (Sigma-Aldrich, 2.8 mg/mL) and maintained in flasks 
(Corning) of 25 mm, at 37 °C, in humified atmosphere with 5% of CO2. Medium 
renewal was performed every 2 - 3 days. For cryopreservation, HL60s are stored in fetal 
bovine serum (20%), in complete serum (70%) and DMSO (10%) in liquid nitrogen. 
 
4.3  Methods 
4.3.1 Bioluminescence assay 
The method that we have used in in vivo experiments is based on animal bioluminescent 
imaging (BLI). This method is nowadays one of the most used by researchers with 
diverse backgrounds due to its low cost, high throughput, and relative ease of operation 
in visualizing a variety of cellular events in vivo.106 BLI allows to continually monitor 
cellular processes or other biological interactions in a single individual, reducing the 
amount of inter-animal variation, thus leading to higher resolution and less data loss.  
The mainstay of this method is the light generated by luciferase enzymes. In our case, 
light produced by firefly luciferase (FLuc) was exploited for bioluminescence assay. 
Fluc is the major luciferase protein studied and it was discovered in Photinus pyralis. 
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This enzyme catalyzes the oxidation of reduced luciferin in the presence of ATP-Mg2+ 
and oxygen to generate CO2, AMP, PPi, oxyluciferin, and yellow-green light at 
wavelength of 562 nm (Figure 4.2).107,108 
 
 
 
Figure 4.2: Bioluminescence reaction promoted by Firefly Luciferase 
 
 
In our experiments Fluc gene was stably transfected in tumor cells with the purpose to 
follow the bioluminescence produced by tagged cells, previously injected into an animal 
model. In this way bioluminescent cells were used to determine the kinetics of 
tumorigenesis and evaluate the efficacy of a chemioterapic treatment, by monitoring 
over time if light output increased or decreased, compared to the initial state. This 
method allowed to follow changes within individual animals without requiring the 
subject to be sacrificed.109 Therefore, the detection of bioluminescence signals within a 
tissue sample was dependent on several factors, including flux of photons from the 
reporter, total number of functional reporters in the cells and location of the reporter 
cells within the tissue sample itself. 
The major challenge in detecting and locating bioluminescent light emission within 
living subjects is represented by an optical imaging device based on highly sensitive 
cooled charge coupled device (CCD) cameras.110,111 CCD detectors are made of sliced 
silicon crystals with high sensitivity to light, able to detect light in the visible and near-
infrared range (400 – 1000 nm). CCD cameras operate by converting light photons that 
strike a pixel with energy of just 2-3eV into electrons. An electrical charge pattern, 
corresponding to the intensity of incoming photons, is read out of the CCD into an 
output register and amplified at the edge of the CCD for digitalization. Thermal noise is 
dramatically reduced since CCD cameras are refrigerated at -90÷ -150 °C. 
 
4.3.2 Procedure 
Experiments in SCID mouse were performed at the Laboratory of Genetic for the 
Production of Animal Models (LiGeMA) at the Animal House of the University of 
Florence. 1x 106 HL60-luc2 cells were intraperitoneally injected in female 5-week old 
mice. Three days after inoculation, the distribution of HL60-luc2 was monitored, in 
order to divide mice in different groups in which subjects possess the same signal. On 
the 5th day after inoculation mice were treated daily for two weeks with: 
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• physiological solution (intraperitoneal) as a control; 
• cytarabine (6.25mg/kg, intraperitoneal); 
• clarithromycin (15mg/kg, gavage) 
• cytarabine+clarithromycin. 
Images were acquired with Photo Acquisition software (Biospace Lab, Paris, France) 
and processed with M3 Vision sofware (Biospace Lab). Bioluminescence was detected 
at 9, 16, 23, 30 and 37 days after HL60-luc2 inoculation. 
 
4.4 Results and discussion 
Figure 4.3 shows the effect of treatment with cytarabine and clarithromycin after 
HL60-luc2 inoculation in SCID mice. Three days after inoculation, 12 mice were 
divided in three groups on the basis of the bioluminescence signal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Clarithromycin reduces leukemia burden in leukemia model. SCID mice were injected 
with HL60-luc2 cell line (5 106 cells). Starting from day 5, animals were treated daily for fourteen 
consecutive days with physiological solution (Control, n=4), cytarabine 6.25 mg/kg, n=4 and 
clarithromycin 15mg/kg, n=4. Images were acquired with Photo Acquisition Software (Biospace 
Lab, Paris, France) and processed with M3 Vision software (Biospace Lab). Color bars represent 
light intensity levels from a minimum of 0.1 counts per minute (cpm) to a maximum of 20 cpm with 
a smoothing parameter equal to 1.295cpm. 
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On the 5th day, treatment with cytarabine or clarithromycin started. Mice were daily 
treated intraperitoneally with cytarabine (6.25mg/kg) and clarithromycin (15mg/kg) for 
two weeks. 
On the 16th day, a considerable reduction of HL60 signal in SCID mice was noticed 
after treatment with clarithromycin, in contrast to what happened to control animals and 
those treated with cytarabine. 
On the 23rd day HL60-luc2 diffused and spread in the body of control mice, as well as 
in mice treated with cytarabine. In contrast with the other two group, 2 mice treated 
with claryhtormicin showed regression of tumor diffusion and survived until 37 days 
after inoculation. 
On the 30th day all mice in the control group died; 1 mouse in the cytarabine group died 
and 2 in the clarythromcin group died. Only 2 mice treated with clarithromycin 
survived, compared with the others. This experimental evidence showed the capability 
of clarithromycin to block tumor development and invasiveness. 
In the second set of experiments 16 mice were divided into 4 groups, each containing 
four animals. The procedure was the same as explained before: after five days from 
inoculation, cytarabine and clarithromycin, alone or in combination were administered 
to mice. Mice in the control group were treated only with PBS. 
The results of this treatments are presented in Figure 4.4, where the survival of each 
experimental group is reported through Kaplan-Meier curves.112 The length of the 
horizontal lines along the X-axis of serial times represent the survival duration for that 
interval.  
 
 
 
Figure 4.4: Kaplan-Meier analysis for each group in the experiment. Blue line underlines the 
survival of the control group, green line is referred to the group treated with clarithromycin, red 
line to the group treated with cytarabine, and orange line to the group treated with cytarabine and 
clarithromycin. 
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Comparing survival curves is important for visualizing the variability within groups 
treated with different drugs. Mice in the control group rapidly died and approximately 
in 30 days tumor invaded all the organs, causing mice death. After treatment with 
clarithromycin and cytarabine the survival increased in comparison with the control up 
to 65 and 100 days, respectively. 
The combination of clarithromycin and cytarabine is thus particularly synergic, causing 
the survival of the mice for more than 100 days. The experiment is ongoing and three 
mice still alive. 
As supported by the literature, clarithromycin increases the leukemia sensibility to 
cytarabine and increases the survival of mice until 120 days. Therefore clarithromycin, 
unlike other hERG blockers, present scarce antiarrhythmic effects and is a promising 
candidate for inclusion in clinical trials. 
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Second Part 
 
Targeting hERG channels: a molecular approach 
through RNA interference 
 
Chapter 1 
 
1.1 RNAi mechanism and discovery 
The discovery of noncoding double-stranded RNA (dsRNA) molecules, capable of 
regulating gene expression in eukaryotic cells by post-transcriptional gene silencing, is 
one of the most relevant advances in molecular genetics.1 Sequence-specific gene 
silencing, known as interference of RNA (RNAi), is a natural occurring molecular 
process that can be experimentally exploited to knock-down any gene of interest. RNAi 
is a molecular technique that allows rapid and cost-effective screening of gene function 
in model organisms2 and mammal cells.3 Moreover, RNAi could have a considerable 
importance in medicine because it may allow the development of treatments against a 
large array of pathologies nonresponsive to conventional therapies. 
RNAi was first observed in petunia flowers by plant biologists. Jorgenesen and 
collaborators introduced the chimeric chalcone synthase (CHS) gene in petunia, in order 
to increase the flowers anthocyanin biosynthesis catalyzed by CHS.4 Contrarily to their 
expectations, the introduction of the transgene blocked the pigment production. The 
concomitant silencing of both ectopic transgenes and endogenous homologous genes 
was called “co-suppression”. A similar phenomenon was evidenced in Neurospora 
crassa two years later. In this case, the post-transcriptional mechanism of gene silencing 
was called quelling, as its relationship with co-suppression in petunia flowers was not 
immediately recognized.5 
Eventually, the post-transcriptional mechanism of gene silencing was clarified in 
Caenorhabditis elegans by Fire and Mello (1998),6 who recognized dsRNAs, but not 
the single strand RNAs, as responsible for gene silencing. The first evidence of this 
mechanism in mammals, was described two years later in mouse early embryos, 
opening the possibility for RNAi human application.7 Finally, in 2001, the discovery 
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that small dsRNA of 21bp (siRNA) were capable of inducing gene-specific-silencing in 
mammalian cells without activating immune-response turned RNAi into one of the most 
promising techniques to control post-transcriptional gene expression in mammals.8 
Although many types of small RNAs have been reported, the three main classes of 
natural small dsRNAs involved in eukaryote gene silencing are: microRNAs (miRNAs), 
small interfering RNAs (siRNAs) and piwi-interacting RNAs (piRNAs). 
 
 
Figure 1.1: RNA interference mechanism mediated by miRNA and siRNA molecules. 
 
 
miRNAs are endogenous products of genome and play an important role in post-
transcriptional regulation of gene-expression. They are initially transcribed by RNA 
polymerase II as a part of a long primary RNA molecule called pri-miRNA, 
characterized by a stem loop structure.9 As shown in Figure 1.1, pri-miRNAs are 
processed by the RNase III enzyme, Drosha, in a pre-miRNA hairpin about 70 nt in 
length, with interspersed mismatches along the duplex and with 2-nt 3’overhang. Pre-
miRNAs are transported in the cytoplasm by the nuclear export factor. In the cytoplasm, 
pre-miRNAs, are processed into miRNA duplexes by a protein complex containing 
Dicer and other functional subunits. Dicer binds and cleaves the pre-miRNA removing 
the terminal loop and leaving a staggered end. Then miRNA duplexes interact with the 
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Argonaute (Ago) protein contained in the pre-RNA Induced Silencing Complex (pre-
RISC). In the mature RISC, the passenger strand is removed and the guide strand is 
integrated in the RISC complex to bind the mRNA target which is cleaved by Ago.10 
siRNAs originate from pseudogenes and from exogenous genes, such as transposons or 
virus, suggesting a role in the control of the genome integrity in response to invasive 
genomes. At variance with miRNAs, the interaction between siRNA and mRNA target 
is fully complementary.11 miRNAs and siRNAs share similarities in size and sequence 
specific inhibitory functions, suggesting a correlation in their biogenesis and silencing 
mechanism.12 
piRNAs are a complex and largely uncharacterized category of silencing inducing 
RNAs. piRNAs play a critical function in protecting germ line cells from invasive 
transposable elements but also have a role in non-gonadal cells.13 
Synthetic siRNA delivery is a well established technique in vitro. However, the major 
challenge for the application of RNAi in molecular medicine is their in vivo infusion. 
For efficient systemic delivery, it is necessary to develop vehicles which can provide 
protection and selective transport to the cells of interest. Currently, the most used 
delivery agents in vivo are lipid-based vectors.14-20 
 
1.2 Importance of delivery procedures 
In vivo administration of siRNAs has some limitations, such as crossing the plasma-
membranes of target cells, unwanted enzyme degradation and activation of immune 
response. Vectors specifically tailored for RNAi were introduced to enhance the 
efficacy of RNAi therapeutics. 
Naked siRNAs is usually employed only in local applications, due to the presence of 
endonucleases in the blood stream and tissues. Examples include delivery to the eye, 
lung, joint and mucosa.21,22 Therefore, the association of siRNAs to carriers is 
imperative for systemic administration to (i) protect the cargo from nuclease 
degradation, (ii) reach the target while avoiding off-target tissues, (iii) facilitate cellular 
uptake.  
Vectors used in gene silencing have been classified as viral or non-viral. Viral-mediated 
delivery exploits the infection ability of retrovirus and adenovirus, and are usually 
employed to induce sustained gene silencing in vitro. However, in vivo applications are 
affected by a number of flaws, such as immune response, insertion mutagenensis, 
toxicity and uncontrolled virus replication. Another limitation is the difficult large scale 
preparation of viruses.23 
On the other hand, for siRNA delivery non-viral vectors can be easily prepared and 
scaled-up, do not provoke immune response and can be safely handled by medical 
operators, without concern for their own health. Non-viral transfection can be 
performed by physical (e.g. electroporation) or by chemical methods. For this latter 
purpose different complexing agents may be used. Examples include inorganic, “hard”, 
nanoparticles (mainly of noble metals, calcium phosphate, or magnetic materials), and 
Second Part -Chapter 1- 
 
 
42 
 
“soft” nanoparticles made by polymers or lipids, peptides or aptamers possibly linked to 
siRNA with covalent bonds. In all cases, the pharmacodynamic behavior and 
cytotoxicity of these formulations need to be investigated to establish the risk-benefits 
of each delivery technique. 
In the next paragraph we focalize on the most used non-viral systems, i.e. lipid-based 
carriers, which are biocompatible and can be prepared in a wide range of formulations.24 
Their peculiarities originate from the striking variety of shape and size shown by lipid 
polymorphism. Indeed, lipids can be arranged in many different aggregates, whose final 
structure results from the balance of intermolecular forces, geometrical constrains, 
counterion binding and hydration.25,26 
 
1.3 Lipid based vectors for nucleic acid delivery 
Micelles are the simplest nanosized aggregates of amphiphilic molecules and are 
spontaneously formed in aqueous media. The nonpolar portions (hydrophobic tails) of 
the constituent monomers are located in the interior, while the polar portions 
(hydrophilic heads) are exposed to water, as schematically shown in Figure 1.2. The 
inside of micelles is a liquid-like hydrocarbon milieu, in contrast with the surface, 
where the monomers are tightly packed.27 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.2. Schematic draw of an amphiphilic molecule and of a micelle 
 
 
Drugs can be encapsulated in different micellar regions, according to their polar/non 
polar characteristics. In particular, non polar lipophilic molecules tends to concentrate 
into the core, whereas polar or amphiphilic compounds are included among the 
monomers or associated to the head region. As aggregates at thermodynamic 
equilibrium, micelles are easily rearranged if the environmental conditions change. 
Thus, the micellar cargo may not been efficiently vehiculated and, in fact, simple 
micelles are scarcely used in drug delivery, at variance with their polymeric analogues, 
which are structurally stable.28 A noticeable exception is the transport of genetic 
material. In this case micelles of cationic amphiphiles, especially di- or tri-valent ones, 
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have proven to be an efficient tool for nucleic acid delivery, since the micelle easily 
deformable shape provides flexible complexing pathways.29 
Liposomes are lipid vesicles in which one or more concentric bilayers are organized 
around an aqueous inner compartment. At variance with micelles, they can’t usually be 
obtained by self-assembling and are not thermodynamically stable. However, easy 
preparation procedures can be devised for liposomes and, due to their biocompatibility 
and versatile formulation, they have been extensively used as carriers for biomolecules 
(Figure 1.3).30-32 
A remarkable advance for intra venous administration has been the production of stealth 
liposomes, which are able to resist blood stream clearance.33,34 Stealth liposomes are 
usually formulated adding PEG (polyethylene-glycol) modified lipids to the other 
starting components or to preformed liposomes. It has been established that the      
(CH2-O-)n units of PEG, being substantially hydrophilic, are located at the liposome 
surface. In practice, PEG is able to exert steric hindrance toward opsonization and 
reticular endothelial recognition.35,36 
 
 
 
Figure 1.3: Possible loading modalities of drug into liposomes: hydrophobic and amphipatic 
compounds are taken up by the lipid bilayer, where they are embedded to varying extent; 
hydrophilic molecules are trapped inside the inner aqueous core. 
 
 
Cationic liposomes are routinely used in nucleic acid delivery, thanks to the electrostatic 
complexation of positive charged lipids with the negative phosphate backbone of 
siRNAs. The balance between positive and negative (amine/phosphate) charge of the 
complex is a prominent factor for transfection efficacy. The overall positive surface 
charge loaded liposomes is also important for the interaction with cell membranes and 
for endosomal escape. It is known that cationic lipids may have toxic side effects. In 
order to decrease toxicity, the surface charge can be reduced by inserting ionizable 
cationic lipids in the bilayer. These lipids have a pKa of 7 or lower.37 
Another improvement concerns the systematic use of cholesterol and of helper lipids 
(1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, DOPE; 1,2-dioleoyl-sn-glycero-3-
phosphocholine, DOPC; etc.), which stabilize the complex, mediate membrane fusion 
and facilitate the cargo release in the cytosol.19,25  
Solid lipid nanoparticles (LNPs) have entered the practice of gene delivery more 
recently with respect to other lipid vectors, but their proven efficiency and easy 
preparation has made them very popular.38-40 Additionally, solid lipid nanoparticles 
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possess good storage stability and can be steam-sterilized or lyophilized. These are 
important issues when experiments proceed from the laboratory to a pharmaceutical 
context. 
Since about 2005 a number of sophisticatedly engineered particles have been proposed 
for RNAi therapeutics (SNALP, Stable Nucleic Acids Lipid Nanoparticle). They are 
positively charged and consist of lipid bilayers made with DLin-DMA (1,2-
dilinoleyloxy-N,N-dimethyl-3-aminopropane), PEG-C-DMA (3-N-[ω-
methoxypoly(ethylene glycol)2000carbamoyl]- dimyristyloxy-propylamine), DSPC (1,2-
distearoyl-sn-glycero-3-phosphocholine) and cholesterol tightly intertwined with 
genetic material.41 Further development of SNALPs lead to formulation which include 
cationic alternatives to DLin-DMA for improving the dose-effect ratio in clinical siRNA 
delivery. 
An example of well characterized SNALP is reported in Figure 1.4. In this work42 a 
microfluidic mixing technology was used by Leung et al. to prepare lipid nanoparticles 
where siRNA is protected by binding to cationic lipids in a tightly arranged core. 
Zwitterionc lipids, some of which modified with PEG, and cholesterol are also part of 
this formulation. Their role is to provide a suitable interface which is at the same time 
biocompatible and not recognizable by the immunosystem. Detailed structural 
investigation was carried out by computing and spectroscopy techniques to establish the 
arrangement of different SNALP components. It is expected that a precise knowledge of 
structural details may be of valuable help for biomedical applications. 
 
 
Figure 1.4. Cross-section and zoom-in views of LNP contains short nucleic acids (in red) bound to 
phospholipid bilayers (cationic lipid DLinKC2-DMA, 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-
di-oxolane in yellow, cholesterol in pink, DSPC in gray, PEG-lipid in violet). Lipid polar region is 
shown in cyan. The lipid composition was DLinKC2-DMA/DSPC/cholesterol/PEG-lipid (4:1:4:1; 
mol/mol) and DNA to lipid ratio ∼0.05 wt/wt.  
 
 
The complex arrangement of components in solid lipid nanoparticles hampers 
unambiguous classification of these vectors. For example, SNALPs may correspond to a 
variety of structures and formulations if they are obtained by different procedures. As a 
general remark, it can be observed that the scenario of lipid-based nanocarriers has 
dramatically evolved since the first non-viral tranfection agents were obtained from 
liposomes and nucleic acids. These complexes were named lipoplexes by Felgner43 and 
their layered structure was clarified by Safinya and coworkers.44 These Authors 
evidenced a subtle mechanism by which the small, highly hydrated polar head of 
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phosphatidyl ethanolamines can change its volume as a response to environmental 
stimuli. In practice, losing or binding water molecules allows to modify the local 
curvature of the vector, favoring cargo release during membrane fusion or endosomal 
escape. 
For the sake of clarity we followed the nomenclature given by the Authors, joint to a 
brief description of each systems. 
The most relevant physico-chemical properties of lipid vectors, size and surface charge, 
are routinely measured by benchtop dynamic light scattering and Zeta potential. Finer 
structural details require more sophisticated investigation by small angle scattering of 
neutron and x-rays, microscopy or spectroscopy (e.g. Magnetic Resonance, Florescence, 
Infra-red). 
Thermodynamic techniques, such as isothermal titration calorimetry, give valuable 
information on the strength of the interactions leading to complex formation and 
preventing cargo release. This is a crucial factor which governs the complex stability in 
different conditions and determines cargo release.45-47 
 
1.4 RNAi therapeutics 
Many diseases are characterized by mutated genes, some of which are over-expressed or 
down-expressed, while others encode truncated or fusion proteins. RNAi could be 
exploited to knock-down over expressed or mutated genes in clinical therapy. 
Synthetic carriers are mainly used for siRNA delivery, whereas engineered viruses are 
used to carry shRNA constructs. Alternatively, siRNA effectors may result in potent 
dose dependent gene silencing, but the overall effect is only transient. In a clinical 
setting this means that repeated treatments have to be administered, requiring large 
amounts of costly drugs. On the other hand, shRNA constructs have the potential of 
being incorporated in cell genome by viral vectors, which allows, in principle, a single 
treatment.14 In clinical applications, viral carrier containing shRNAs are delivered ex 
vivo to the target cells, and then these modified cells are re-infused to patients. On the 
contrary, synthetic carriers are well suited for systemic delivery, due to high 
biocompatibility and safety. In the following sections we present a survey on clinical 
trials where lipid-based carriers have been used for siRNA delivery.15, 16, 48, 49 
 
1.4.1 Genetic and systemic disorders 
A dominant negative genetic disorder is an abnormal state in which a mutant allele 
prevails over its second normal copy. In this context RNAi can be used for selective 
inhibition of the mutant gene expression. 
The usefulness of this strategy has been demonstrated for several genetic disorders, such 
as amyotrophic lateral sclerosis, Huntington’s and Alzheimer’s disease, slow channel 
congenital myasthenic syndrome, spinocerebellar ataxia type 3, and sickle cell 
anemia.50,51 Although none of these studies have progressed into human trials yet, they 
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show the utility of RNAi technology as a new class of therapies for genetic disorders in 
preclinical models. 
TransDerm (Santa Cruz, California, USA) is performing a clinical trial for the treatment 
of Pachyonychia Congenita. The pharmaceutical protocol is based on a local injection 
of naked siRNA against keratine 6a gene. To overcome pain and low toleration, 
TransDerm is currently developing an alternative delivery method that includes topical 
ointment with lipid-based carriers (GeneCreme).52 
Tekmira Pharmaceuticals Corporation (Burnaby, British Columbia, Canada) has 
developed a number of SNALP formulations currently undergoing clinical trials. In 
particular, TKM-ApoB against hypercholesterolemia is based on PEG-C-DMA, DLin-
DMA, DSPC and cholesterol in a 2/40/10/48 molar percent ratio. The size of the 
resulting vector is 77-83 nm and siRNA encapsulation efficiency is 92-97%.53 To 
reduce hypercholesterolemia the chosen siRNA is designed to specifically silence the 
expression of Apolipotrotein B (Apo B) into liver. ApoB is the main component of low-
density lipoproteins (LDL), carrying cholesterol and triglycerides through the blood 
stream to various tissues, where ApoB enhances the uptake of LDL particles into cells. 
A Phase I trial involved 23 subjects. In the two patients that received the highest dosage, 
ApoB protein and the correlated LDL concentration were temporarily reduced by about 
20%. This trial was terminated because one subject developed flu symptoms suggesting 
immune system stimulation. 
Another vector, classified as Lipidoid-nanoparticles (LNP), was developed by Alnylam 
(Cambridge, MA, USA) against hypercholesterolemia. It is made with 98N12-5 • 4HCl 
(Figure 1.5),54 cholesterol and methoxypoly(ethylene glycol)- 1,2-dimyristoyl-sn-
glycerol, mPEG2000-DMG 
 (42/48/10 in ethanol). siRNA is incorporated into LNP at weight ratio siRNA/total 
lipids 1/7.5 (ALN-PCS). Particle diameter is about 50 nm, and siRNA entrapment is 
>95%.55 
In this study siRNA targets PCSK9 (proprotein conventase subtilisin/kexin type 9), a 
serum protein regulating LDL metabolism. Knockdown of this protein is associated 
with increased LDL uptake by the liver. A Phase I trial involved 32 subjects with dose 
ranging from 0.015 to 0.400 mg/kg. Intravenous administration resulted in rapid, dose-
dependent, and durable silencing of PCSK9 level in plasma (84%) and correlated 
reduction of Low Density Lipoprotein cholesterol, LDL-c (50%), in the highest dose 
group.56 
Alnylam has also developed two different SNALPs for the amyloidosis disease, where 
the mutant transthyretin protein (TTR) causes deposit of amyloid fibrils in extracellular 
space of various tissues. In both SNALPs the siRNA sequence was the same and 
silenced TTR protein. In collaboration with Teckmira, Alnylam formulated a first 
generation SNALP (ALN-TTR01), based on DLinDMA, specifically designed to be 
taken up by liver hepatocytes. The phase 1 is now completed and ALN-TTR01 was well 
tolerated with 25-81% TTR suppression from a single 1 mg/kg dose with no serious 
toxicity or immune-response.57 
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Figure 1.5: Chemical formulations of DLinDMA, DLin-KC2-DMA, Lipidoid 98 N12-5, DLin-MC3-
DMA, L-319, GalNac conjugate to siRNA and ATUFECT01. 
 
 
The second SNALP is based on the newly synthesized lipid DLin-MC3-DMA, 
dilinoleylmethyl-4-dimethylaminobutyrate (Figure 1.5) (ALN-TTR02), developed by 
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Jayaraman et al.58 This lipid was mixed with DSPC, cholesterol and PEG lipid in molar 
ratio 50/10/38.5/1.5. In phase 1 trial a reduction of 82% was found with the lowest dose 
(0.15 mg/kg), showing that the knockdown effect is enhanced by one order of 
magnitude with respect to ALN-TTR01. Phase II results show that multiple doses of 
ALN-TTR02 led to robust and statistically significant knockdown of serum TTR protein 
levels of up to 93%.59 
Considering the good results obtained with DLIn-MC3-DMA, this second generation 
LNP technology is used to delivery PCSK9 siRNA (ALN-PCS02). With this new 
formulation in phase I a reduction of LDL-c of 50% with 0.25 mg/kg dose, instead of 
0.4 mg/kg, was found.60 
For the treatments of amyloidosis, Alnylam has developed another RNAi drug called 
ALN-TTRsc targeting transthyretin. ALN-TTRsc is characterized by siRNA conjugated 
to a triantennary N-acetylgalactosamine (GalNAc) a lipid like ligand which enables 
hepatocytes uptake by the asialoglycoprotein receptor. This compound was 
administered to non-human primates, resulting in a 80% reduction of TTR at doses as 
low as 2.5 mg/kg. Upon completion of the Phase I trial, concluded only in UK, Alnylam 
is planning to start a Phase II clinical study of ALN-TTRsc in patients by the end of 
2013. Considering the effective dose, the solubility of GalNAc-siRNA Alnylam 
proposes a subcutaneous administration ALN-TTRsc in human study at volume of 
approximately 1mL.61 
A novel class of third generation of LNPs, called rapid elimination lipid nanoparticles 
(reLNPs) was develop in order to enhance biodegradability and facilitate the elimination 
to deliver siRNA to the appropriate intracellular milieu. L319 (Di((Z)-non-2-en-1-yl) 9-
((4-(dimethylamino)butanoyl)oxy)heptadecanedioate) in the biocleavable component of 
reLNP-siTTR which allowed to obtain10-fold improvement compare with second 
generation LNPs.62 
 
1.4.2 Viral infections 
There are numerous studies that underline efficacy of RNAi against hepatitis viral 
infection in vitro63 and in vivo.64 In animal models, the usual delivery method is 
hydrodynamic intravenous injection. However, this is not applicable in the treatment of 
human hepatitis.65 
Herpes simplex virus infection is treated in a mice model by siRNA microbicide with 
distinct viral targets. Vaginal applications of lipid encapsulated siRNAs have been used 
to block the infection with no apparent toxicity.66, 67 
Tekmira corporation has developed SNALPs (TKM-Ebola) against the Zaire species of 
Ebola virus (ZEBOV) that induce hemorrhagic fever with mortality rates as high as 
90%. This SNALP is made with cholesterol, dipalmitoylphosphatidylcholine (DPPC), 
and DLinDMA and incorporates a combination of modified siRNAs targeting the 
ZEBOV L polymerase (EK-1 mod), viral protein 24 (VP24-1160 mod) and VP35 
(VP35-855mod). The particle size is between 81-85nm. Pre-clinical studies were 
conducted on two groups of macaques: the first one (n=3) received four subsequent 
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administrations of TKM-Ebola at 2 mg/kg per dose (bolus intravenous infusion), while 
the second group (n=4) received seven doses, after ZEBOV infection. These post-
exposure treatments protected two of three monkeys in the first group and all macaques 
in the second group from ZEBOV infection.68 Considering the good results obtained in 
non-human primates, Tekmira started Phase I clinical trial in February 2012.69 
 
1.4.3 Cancer 
The most promising RNAi application is in cancer therapy, where it may offer precise 
genetic control and provide a viable alternative to conventional drugs. In fact despite 
enormous effort has made in biological research, cancer pathology remains one of the 
most common cause of death in the world. 
The advent of the new “-omics” technologies open the possibility to individuate specific 
biomarkers allowing the creation of cancer molecular profile for each patient. 
Biomarkers include mutated and overexpressed genes, as well as genes encoding fusion 
proteins.70 The corresponding mRNAs should be siRNA targets. Moreover, the 
possibility exist to design vectors carrying different siRNAs for a multi-target therapy 
with the advantage of reducing the capacity of cancer cells to develop resistance. 
Another possibility is silencing genes involved in the resistance to chemotherapic drugs, 
in order to restore their sensitivity.71 
In latest years, cancer therapies provide new formulations of lipid based vectors for 
siRNA delivery as a valid alternative to conventional therapy. In addition to the 
classical characteristics of lipid vectors, it is possible to exploit the nanoparticle 
tendency to accumulate in cancer tissue rather than in healthy ones (Enanched 
Permeability and Retention effect).72 In fact, after activating a neo-angiogenesis 
process, cancer cells produced blood vessels with abnormal form and architecture, 
which present wide fenestrations. This enhanced permeability leads to the transport of 
supply nutrients, oxygen and macromolecules larger than 40 kDa, allowing rapid tumor 
development. Thus vectors with size range of 50-200 nm have an easy access to cancer 
cells. 
Current clinical trials with siRNA and lipid-based vectors for anti-cancer therapy are 
summarized in Table 1.1. 
Sood and coworkers have shown that Ephrin type-A receptor 2, EphA2 is frequently 
expressed in ovarian and other solid cancers, but it is present at low levels in normal 
tissues. So, this protein is an attractive therapeutic marker.73 The same group developed 
a neutral liposome for siRNA targeting EphA2.74 The use of zwitterionic lipids, such as 
DOPC, allows efficient uptake of siRNA-complexes into the cell. DOPC was mixed 
with siRNA at weight ratio 1/10 siRNA/DOPC in terbuthanol. The tween-20 surfactant 
was added in weight ratio 1/19 tween-20/ siRNA complex. This complex was 
administered to an orthotopic mouse model of ovarian cancer. After three weeks of 
treatment, tumor growth was reduced. In particular, the effect was dramatically 
increased in combination with paclitax.  
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Atugen (Silence therapeutic subsidiary; AG, Berlin, Germany) has developed 
AtuPLEX, a siRNA-lipoplex, for the treatment of solid tumors. These liposomes are 
made with the novel cationic lipid AtuFECT01(β-L-arginyl-2,3-L-diaminopropionic 
acid-N-palmityl-N-oleyl-amide trihydrochloride), the helper lipid DPhyPE (1,2-
diphytanoyl-sn-glycero-3-phosphoethanolamine) and the PEG2000-DSPE (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]) 
in molar ratio of 50/49/1.75 Liposome dispersions were mixed with siRNA to obtain 
lipoplexes at the +/- 4/1, size of ~118 nm and Zeta potential of +46 mV. In mouse 
model this formulation induced down-regulation of endothelia specifically expressed 
genes (such as CD31 and Tie2), demonstrating the applicability of this system in vivo.76 
The same lipid-based vector with a siRNA targeting protein kinase 3 (PKN3) named 
Atu027 is currently used in a Phase I clinical trial for the treatment of advanced solid 
tumor. Silencing PKN3 results in the inhibition of tumor angiogenesis. 
Tekmira proposed a first generation SNALP TKM-PLK1 targeting polo-like kinase 1, a 
protein involved in tumor cell proliferation, also validated as an oncology target. LNP is 
composed by DLinDMA, cholesterol, DSPC and PEG-c-DMA with lipid/siRNA mass 
ratio 9/1.77 Preclinical studies showed that TKM-PLK1 selectively killed cancer cells 
while spearing adjacent healthy tissues. TKM-PLK1 started a Phase I clinical trial in 
December 2010 which is now completed. This trial involved 52 subjects with advanced 
solid tumors. The dose range tested in this trial was 0.15-0.90 mg/kg, with a total of 105 
doses administered.  
Alnylam has developed a first-generation lipid nanoparticle or SNALP (ALN-VSP) to 
deliver two different siRNAs targeting critical genes for the proliferation and 
development of cancer cells: the vascular endothelial growth factor (VEGF) and kinesin 
spindle protein (KSP). ALN-VSP has a diameter of 80-100 nm and is essentially non-
charged with a Zeta Potential of 6 mV at pH 7.4.78 In Phase I trial the ALN-VSP was 
administered through intravenous injection in 41 patients with advanced solid tumors 
involving liver. Results demonstrate that ALN-VSP induces tumor regression (after two 
months of treatment) 42% of patients treated at doses of 0.4 mg/kg. ALN-VSP are well 
tolerated with no clinically significant changes in liver function. The same patients 
showed low grade of fatigue (24%), nausea (17%) and fever (17%). 
Koldehoff et al. have developed anionic liposomes for siRNA delivery by targeting the 
fusion oncogene bcr-abl.79 This gene results from mutual traslocation of chromosome 
22 and 9, producing the so called Philadelphia chromosome, which is characteristic of 
chronic myeloid leukemia (CML). bcr-abl siRNA was diluted 1:10 in 10% anionic lipid 
solution (100 g soya been oil, 25 g glycerol, 6 g egg phospholipid per liter) forming 
siRNA chylomicrons in lipid solution (siRNA-DLS).80 Anionic liposomes have less 
cytotoxicity compared to cationic liposomes and in this case they were able to preserve 
siRNA integrity in biological media. The siRNA-DLS complex was intravenously 
injected and subcutaneously into CML nodes of one female Imatinib resistant CML 
patient (clinical study sponsored by Duisburg-Essen University, Germany). This 
treatment didn’t show severe side effects, although the knockdown of bcr-abl was not 
maintained 22 days after injection. Additional injection of siRNA-DLS indicated a 
growing resistance to siRNA therapeutics. 
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Table 1.1.  Recent clinical trials for cancer diseases based on siRNA delivery (till 2013) from the web site www.clinicaltrials.gov  
Drug 
Intriduction in the 
body - Delivery 
Vehicle Disease Target gene Phase Stage 
Clinical/Trials: gov 
Identifier 
Company 
siRNA-Epha2-DOPC Intravenous injection DOPC liposome advanced solid tumor Epha2 1 Not yet recruiting NCT01591356 MD Anderson 
Cancer Center 
Atu027 Intravenous injection AtuPLEX® Advanced solid tumor PKN3 (protein Kinase C) 1 Completed NCT00938574 Silence therapeutic 
TKM-080301 Hepatic arterial 
injection (HAI) 
SNALP Colorectal, Pancreas, 
Gastric, Breast, 
Ovarian and 
Esophageal cancer 
with hepatic 
metastasis or primary 
liver cancers 
PLK1 (Polo-like-kinase 
1) 
1 Completed NCT01437007 Tekmira 
Pharmacueticals 
Corporation 
ALN-VSP02 Intravenous injection SNALP Solid tumors KSP (Kinesin Spindle 
Protein) and VEGF 
1 Completed NCT00882180 Alnylam 
Pharmaceutical 
Bcr-abl siRNA intravenous injection Anionic liposome Chronic Myeloid 
Leukemia (imatinib 
resistance) 
bcl-abl 1 Completed N/A University of 
Duisburg 
pbi-shRNA™STMN1 
LP/ pbi-
shRNA™PDX LP 
Intratumoral injection Bilamellar invaginated vesicle Advanced and/or 
Metastatic Cancer 
Stathmin-1 (STMN-1) 1 Recruiting NCT01505153 Gradilis, Inc. 
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Gradalis® is currently conducting two different clinical trials involving cationic 
liposomes encapsulating shRNA constructs. pb-shRNA™ STMN1-LP contains shRNA 
able to knockdown Stathmin 1, a protein critically involved in microtubule assembling 
and metastatic phenotype.81 
pb-shRNA™ PDX-1 LP has been shown to silence pancreatic and duodenal homeobox 
factor1 (PDX-1), overexpressed in many types of solid tumors. shRNA constructs were 
encapsulated in two bilamellar invaginated vesicle lipoplexes (BIV-L). Extruded 
DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate), 
cholesterol liposomes (BIVs) interact with nucleic acids which attract a second BIV to 
this complex. Expanding electrostatic interactions with shRNA constructs cause 
inversion of the larger BIV and total encapsulation of the nucleic acids in a sandwich 
between lipid bilayers.82 
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Chapter 2 
 
2.1  Divalent cationic surfactant: structural description and      
general properties  
Gemini are dimeric surfactants, made up by two amphiphilic moieties, covalently 
connected at the level of the head groups by a spacer (Figure 2.1)  
 
  
 
Figure 2.1: Scheme of dimeric surfactant . 
 
 
In aqueous media, above a specific concentration (critical micelle concentration, cmc) 
dimeric surfactant self-assembly into micelles where non polar portions are located in 
the interior while polar heads are exposed to water.  
The current interest in such surfactants arises from three essential properties. Dimeric 
surfactants are characterized by cmc that are one or two orders of magnitude lower than 
for the corresponding conventional monomeric surfactant. For example the cmc of the 
Gemini surfactant 12-2-12 (dymethylene-1,2-bis (dodecyldimethylammonium 
bromide)) is about 0.055 mol/L, whereas that of the corresponding monomeric 
surfactant DTAB (dodecyltrimethylammonium bromide) is 0.5 mol/L. 
Dimeric surfactants are much more efficient than the corresponding monomeric 
surfactants at decreasing the surface tension of water. This efficiency is often 
characterized as the surfactant concentration (C20) required for lowering the surface 
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tension of water by 0.02 N/m. The values of C20 for D2 and DTAB are 0.0083 and 
0.21wt%, respectively. 
Aqueous solutions of dimeric surfactants with short spacers can have very high 
viscosities at relatively low concentrations whereas solutions of the corresponding 
monomeric surfactants have low viscosities. For instance the viscosity of aqueous 
solutions of DTAB is larger than that of pure water up to a surfactant concentration of 
the least 10 wt% whereas 5 wt% solution of 12-12-12. 
The different behavior of dimeric surfactant, in comparison with conventional 
surfactant, depends on the distribution of distances between head groups in micelles of 
these two type of surfactants. In dimeric surfactant this distribution depend not only on 
the distance between polar heads of different molecules but also on the length of the 
spacer. The length is determined by the bond extension and bond angle of the atoms 
present in the spacer group. The effect of the chemical link between the head group on 
the packing of surfactant alkyl chains in the micelle core are expected to affect strongly 
the curvature of surfactant layers and thus the micelle shape and the properties of the 
solution. 83, 84 
Dimeric surfactants have been also reported to have better solubilizing, wetting, 
foaming and lime-soap-dispersing properties than conventional surfactants. 
It is possible to synthetize dimeric surfactants by using two of any type of the presently 
known amphiphiles, identical or different connected between a spacer of varied 
chemical nature, hydrophilic or hydrophobic, rigid or flexible. The enormous variety of 
surfactant structures that could be synthetized, leads to numerous micellar shapes with 
diverse physic-chemical properties, making these molecules versatile for different use.  
Nowadays cationic dimeric surfactants are also studied, in order to use them in the 
rational design of vector for RNAi therapeutics. As previously discussed in Chapter 1 
naked siRNA are not able to cross plasma membrane and it is necessary to develop new 
vector that can bind and deliver these molecules until the target. Since viral vectors are 
not safe and produce immunogenicity, the development of non-viral vectors has become 
urgent. In this field the use of dimeric cationic surfactants could enhance siRNA 
delivery not only for their capability to interact with the negative backbone of siRNA, 
but also for their ability to self assembly in water unlike conventional phospholipid 
which need energy input (by sonication or extrusion) to form liposomes. 
 
2.2 SH14 and Gemini properties 
In our work we focuse on the studies of three Gemini with general formula:  
 
C12H25-N+(CH3)2-CnH2n-N+(CH3)2-C12H25, 2Br- 
where n = 3, 6, 12 (henceforth called 12-n-12) (Figure 2.2
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             12-3-12                                    12-6-12                                                  12-12-12 
 
Figure 2.2: shows the chemical structure of 12-3-12, 12-6-12 and 12-12-12 
 
 
or a triazine-based surfactant (Figure 2.3): 
 
HS-C2H4-(N3C3)2+-NH-C3H6NH2, 2CF3COO-   
                       | 
                      NH-C14H29 
 
henceforth called SH14. 
 
N N
NHNHS NH
HN
NH2
 
  
Figure 2.3: shows the chemical structure of SH14. 
 
The three Geminis are characterized by two amphiphilic molecules, each consisting of a 
quaternary ammonic group and a hydrophobic chain of 12 carbons. The polar heads are 
N N
Br
Br
N
N
Br
Br
N NBr
Br
2- 
+  2 CF3COO- 
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connected with a spacer group consisting of an alkyl chain of three different length         
(-CH2)3, D3, (-CH2)6, D6 and (-CH2)12, D12.  
SH14 are characterized by an alkyl chain of 14C and a triazine ring with two positive 
charges. These molecules are characterized by a –SH group that makes possible an S-S 
bond between two molecules.  
Gemini surfactants were synthetized at the Montpellier University by Dr. Martin In, 
while SH14 was synthetized at Politecnico of Milan in collaboration with the Dr. 
Gabriele Candiani. The synthesis of the four surfactants used in this work is reported 
elsewhere. 85, 86 
Powders of these surfactants are stored at room temperature and solubilized in water 
MilliQ RNAasi free. 
Of these two surfactant classes, Geminis are the most studied.87-90They have been 
extensively investigated in research topics of therapeutic interest, such as drug delivery 
and gene therapy, usually in conjunction with phospholipids to form liposomes or lipid 
nanoparticles. In particular, both plasmids and siRNA have been successfully 
complexed with Gemini surfactants. The fusion process of gemini-based liposomes with 
model cell membranes has also been followed and elucidated by Differential Scanning 
Calorimetry (DSC) and fluorescence spectroscopy.91 
Although SH14 is less studied, it appears to be a promising transfection reagent. SH14 
molecules are able to dimerize forming -SS- bound upon DNA and form lipoplex, 
capable of realizing  nucleic acids in the intracellular mielieu.92 Alike for Gemini 
surfactants, SH14-based formulations have been shown to be highly effective for 
transfection purposes, which open the possibility to use these systems in clinical 
protocols. 
 
2.3 Physico-chemical characterization of micelles 
Molecular weight (g/mol) and cmc (M) values of these four surfactants are shown in 
Table 2.2. 
 
Surfactant Molecular Weight, g/mol cmc, M 
D3 624.37 9.6 10-4 
D6 666.42 10-3 
D12 750.52 3.7 10-4 
SH14 666 1.46 10-3 
 
Table 2.2: Molecular weight and cmc values determined by conductivity experiments of the four 
surfactants. 
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12-n-12 micelles are characterized also by SAXS measurements, on the ID02 beam line 
at the ESRF European Sinchrotron Radiation Facility, Grenoble, France. The 
wavelength of the incident photons was λ= 1Å and sample-detector distance was 1m, 
allowing for scattering wavevectors in the range 8 10-3 < q(Å-1) < 0.7, where q is the 
defined as 		 = 	 sin 	, θ being the scattering angle.  
The measurements were performed using a two-dimensional multiwire proportional gas 
counter and samples are studied at room temperature in a quartz capillary.  
Gemini surfactant aggregates are analyzed in function of the concentrations and linker 
length. Samples studied are prepared at concentrations ranging from 6 10-4M to             
6 10-2M. 
SAXS curves of micelles were analyzed by a software called GENFIT designed by Dr. 
Francesco Spinozzi at the University of Ancona. The best fit  is written as a linear 
combination of M models chosen by the user from a wide list,  = ∑ 	 . 
The parameters of the models (such as thicknesses, scattering length densities, etc.) and 
the weight parameters  are found by minimizing the functional 
 = 1  ∑  !
"#
! [%&'	!	 − !], where  is the number of  recorded 
points and ! is the experimental standard deviation of the i-th point. 
At concentrations slightly below the cmc, a weak but detectable excess scattering 
intensity was observed, indicating that premicellar aggregation may take place. These 
SAXS diagrams could not be fitted with a specific model due to low intensity and no 
shape features. Submicellar anomalous behavior of Gemini surfactants was also 
reported for surface tension and conductivity, which was explained by either premicellar 
aggregation or by different binding modalities between divalent surfactants and one or 
two counterions. 
At concentration higher than the globular micelles (spherical or cylindrical) were found 
up to ~10-3M, while above this value a shape transition took place, inducing the 
formation of thread like or lamellar structures. 
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Chapter 3 
 
3.1 Complexation of siRNA and cationic micelles  
When combined with siRNA, non-viral vectors give complexes whose structural 
features are from nano- to micro-scale range.93-96 These complexes show a tendency to 
time evolution and are often unstable over long periods. It appears therefore that 
transfection agents are multifaceted systems and in depth investigation requires 
powerful techniques, along with more standard characterization, which provide basic 
physico-chemical information (e.g. overall size and surface charge). Large scale 
facilities offer the opportunity to perform high resolution Small Angle Scattering of 
neutrons and X-rays (SANS and SAXS, respectively),97,98 that can be used to obtain 
insights of nanosystems, such as their internal composition.99 In some instances, the 
interactions at play in the control of the system stability have also been inferred.100 
Considering that the state of the complex used for transfection strongly depends on the 
kinetic pathway followed during formation, time resolved experiments can give 
information on the mechanisms that determine the resulting structure and size. Actually, 
the final state of the mixture corresponds to liquid-liquid phase separation where the 
concentrate phase of complexes coexists with a dilute phase of released counterions. 
Nucleic acid-lipid complexes have been often studied after full phase separation (i.e. by 
analyzing the pellet),101-103 or at the stage of their formation to point out the self-
structuring of components. They are rarely studied in the early stage of formation, when 
they are still dispersed at the macroscopic scales. Following a previous structural study 
by Dynamic Light Scattering (DLS), Zeta Potential and SANS.104 
 
3.2 Time resolved SAXS to study the complexation of siRNA 
by cationic micelles of divalent surfactants 
3.2.1 Materials 
We analyzed the kinetics of formation and the structural evolution of complexes 
obtained from a siRNA interacting with micelles of cationic divalent surfactants. 
Micelles are formed by four type of cationic surfactant 12-3-12, 12-6-12, 12-12-12 and 
SH14 (see Figure 2.2 and 2.3). 
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The siRNA chosen for this study has the following nucleotide sequence: 
 
sense:               5’ GAUAAAGGAGCGAACCCACUU 3’ 
antisense:   3’ UUCUAUUUCCUCGCUUGGGUG 5’ 
 
This siRNA is able to downregulate the expression of hERG1 potassium channel, which 
is involved in the pathogenesis of severe human diseases such as glioblastoma 
multiforme, leukemia, gastric and colon cancer.105 
siRNA powder are storage at -20°C and solubilized in water Milli Q RNAasi free. 
 
3.2.2 Methods 
SAXS experiments are used to investigate the structure of the materials: solids, liquids 
or gels. X-rays photons interact with electrons and allow to obtain information from the 
distribution of electron density in the heterogeneous matter. The technique provide that 
a monochromatic beam of incident wave vector  is selected and falls on the sample. 
The ray interacts with the electrons and is scattered. The intensity of the scattering is 
collected by a detector in function of the scattering angle 2. Since elastic interactions 
do not provided energy transfer, the modulus of the final wave vector   is the same of 
the incident , so  	 		=	


. The relevant parameter to analyze the interaction is 
the scattering vector  	 		  . The intensity of the scattering is  	


sin  and 
the standard unit of q is Å-1. (Figure 3.1) 
 
 
 
 
 
 
 
 
 
Figure 3.1: X-rays scattering scheme. 
 
 
The scattered intensity I(q) is the Fourier Transform of g(r), the correlation function of 
the electronic density r(r), which corresponds to the probability to find a scatterer at 
position r in the sample if another scatterer is located at position 0: elastic x-ray 
scattering experiments reveal the spatial correlations in the sample. Small angle 
 
 
 
 
 
 
 
 
beamstop 
detector 
sample 
X-Rays 
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scattering experiments are designed to measure I(q) at very small scattering vectors 
~ 1 , with 2 ranging from few micro-radians to a tenth of a radian, in order to 
investigate systems with characteristic sizes ranging from crystallographic distances 
(few Å) to colloidal sizes (up to few microns). 
For a suspension of uniform particles, the normalized scattered intensity after 
substraction of solvent background is given by: 106 
 
 = 3	45	6	7	 
 
where N is the number of density of scattering particles, V is their volume, Δρ is the 
scattering contrast, 6	is the form factor describing the shape of the particles and 
7 is the structure factor of interactions.  
A typical small angle scattering intensity profile is shown on Figure 3.2 where the 
intensity is plotted versus q in the range qmin-qmax defined by the experimental set-up and 
usually fixed  by geometric limitations. 
 
 
 
Figure 3.2: Panel A shows the feature of a typical X-ray scattering profile, panel B indicate the size 
of the windows in faction of q. 
 
 
A measurement made at a given < allows to investigate the density fluctuations in the 
sample on a distance scale = = > .  It is equivalent to observe the system through a 
circular window in real space of a diameter > . The smallest observation window, given 
by =?& = @AB allow to determine structural characteristic of biggest objects present in 
solution while a largest window allow to obtain information about smallest particle. 
The q range of small angle experiments is usually divided into three main domains: 
• At high q domain the window is very small: there is a contrast only at the 
interface between the two media 
• At intermediary zone is the order of the “elementary bricks” in the systems. At 
this level the form factor P(Q) can be measured.  
• At low q domain the window is large and the structure factor can be 
obtained.107 
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Time resolved Small Angle X-ray Scattering was carried out at the high brilliance ID02 
beamline of the European Synchrotron Radiation Facility (Grenoble, France). (Figure 
3.3) 
 
 
 
Figure 3.3. European Synchrotron Radiation Facility (Grenoble, France) 
 
 
The sample to detector distance was 1.5 m, corresponding to a q (magnitude of the 
scattering vector) range 0.080-3.8 nm-1. q is defined as  = 1 CDE where θ is an half 
of the scattering angle and λ, the X-ray wavelength  (λ= 0.1 nm). 
siRNA/micelles complexes were prepared by mixing equal volumes (100 µL) of MilliQ 
grade water solutions of cationic surfactant (either 2.5 10-3 M or 1.25 10-3 M) and 
siRNA at the appropriate concentration to obtain the desired charge ratio: FG = [ ][H]. 
From previous Zeta Potential experiments,104 we know that at CR < 1, these complexes 
are positively charged, whereas at CR > 1 they are negatively charged.  
In kinetic experiments the starting surfactant and siRNA solutions were mixed by a 
stopped-flow device (SFM-400) Figure 3.4 from Bio-Logic (Claix, France), consisting 
of four motorized syringes interconnected through three mixers. The exit of the last 
mixer is coupled to the scattering cell, a quartz capillary with 2 mm diameter. The flow 
is stopped by a hard-stop placed at the end of the flow line and it is activated at the end 
of the mixing sequence. The dead time was primarily determined by the time to transfer 
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the mixture from the last mixer to the beam crossing point on the capillary cell, as 
described elsewhere. 
 
 
 
Figure 3.4: Panel A shows SFM-400 stopped-flow device. S stend for syringe (each controlled by stepper 
motors), M for mixers and C is the svattering cell (quartz capillary). Panel B shows stopped-flow set-up 
installed at the SAXS instrument with optimased cone for SAXS. White arrows indicates the X-ray beam 
direction. 
 
 
In the present experiments all systems contained a fixed amount of surfactant, which 
after mixing was 1.25 10-3 M or 6.25 10-4 M, for two different sets of samples. Notably, 
both these concentrations are higher than the critical micelle concentration cmc 103 (see 
Table 2.2). Measurements on complexes were performed at 5 mL/s flow rate with 
acquisition time of 10 ms. The data acquisition cycle was triggered at the beginning of 
the fast mixing phase and the hard-stop was activated at the end of this phase. Each 
cycle consisted of a total of 80 or 60 frames, collected in three different time groups: 
first group each 0.15 s, second group each 2-3 s and third group each 40-60 s. 
The 2-dimensional scattering patterns were normalized to an absolute intensity scale 
after applying the detector corrections for spatial homogeneity and linearity. 
Normalized SAXS patterns were azimuthally averaged to obtain the 1-dimensional 
scattering profiles (I(q) vs q). Both sample and background (water) measurements were 
recorded at the same spot of the stopped-flow capillary cell to ensure an accurate 
subtraction of the background. On the whole, more than 5000 diagrams were recorded 
and analysed, since each measurement was repeated at least twice, to assure 
reproducibility of behaviour. This is a critical issue when describing systems like those 
reported in this paper, which are basically out of equilibrium. 
Static experiments on micelles were also performed in a flow-through capillary of 2 mm 
diameter at a sample to detector distance of 0.8 m (0.1 nm-1 < q < 8 nm-1). In this case 
the acquisition time was 100 or 200 ms. 
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3.3 Results and discussion 
SAXS diagrams of siRNA complexed with 12-6-12 at two molar ratios, i.e. CR = 
0.75 and CR = 1.25 are shown in Figure 3.5. The reference curves of pure siRNA 
and 12-6-12 are also reported in this figure for comparison. The charge ratios 
were chosen in order that most of the components were in the complexed form, 
which means close to CR=1. This simplifies the SAXS patterns as it minimize 
free micelles and free RNA and allows higher time resolution since most of the 
signal is given by the complex. Charge ratio close to neutrality might facilitate 
phase separation, especially when the complexing agent is a polymer or a 
liposome or when the nucleic acid is a high mass fragment. In general, the 
kinetics of phase separation depends on the size of the nucleic acid and on the 
concentration of starting components. Here we took advantage of the siRNA’s 
small size and we adjusted the concentration so that the systems were stable over 
the whole measuring time and longer (more than 30 minutes).  
In the micelle curve, the broad maximum at 2 nm-1 results from the shell-like structure 
of the counterions cloud around the hydrocarbon core, reflecting the diameter (3.14 nm) 
of 12-6-12 micelles.108 Immediately after mixing, a marked increase of the intensity at 
low q, pointed out the formation of larger scattering objects in solution and the 
appearance of a quasi-Bragg peak at higher q indicated core structuring within the 
newly formed aggregates. Specifically, for this siRNA/12-6-12 system the peak 
maximum (qmax) was located at 1.72±0.005 nm-1 and 1.70±0.005 nm-1 for CR = 0.75 
and 1.25, respectively that is slightly shifted in comparison with the maximum of the 
micelle curve. This suggested that siRNA is intercalated in between micelles. The qmax 
values of siRNA/12-6-12 complexes correspond to repeat distances I =   of 
3.65±0.005  nm and 3.69±0.005 nm. 
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Figure 3.5: SAXS intensity diagrams of 12-6-12 micelles, siRNA and complexes at two 
charge ratios (CR = 0.75 and CR = 1.25) recorded after 50 ms from mixing. In the complex 
solution the total surfactant concentration (1.25x10-3 M) is 1.5 times the CMC of 12-6-12. In 
the reference systems siRNA is 4.5x10-5 M and 12-6-12 is 1.25x10-3M. 
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The intensity scattered by complexes in the large q region exceeded the micelles’ 
level by ∼ 3-5x10-5 mm-1, in agreement with the expected contribution of Br- 
counterions which are transferred from the micelle surface to the bulk solvent 
upon complex formation. In fact, the incremental background due to ions with n 
electrons at molar concentration J is given by:109 
 
IBr(q)=c Na fe2 n2                                
 
where Na is the Avogadro number, fe is the Thomson scattering length (2.82x10-13 cm), 
and J is the concentration of ions per unit volume released from Gemini micelles 
(c=1.25x10-3 M ). 
By taking =0.52 as the dissociation degree of 12-6-12 micelles104 and 	E = 36, the 
value of 4.0x10-5 mm-1 was obtained. 
Counterion release is a relevant step in the complexation of nucleic acids by positively 
charged nano-aggregates and, it is considered the driving force for the spontaneous 
nature of this process.110-112 This behavior was observed for the three Gemini surfactants  
and also for SH14. 
The intensity diagrams of the siRNA/SH14 systems are reported in Figure 3.5. These 
curves have a similar shape to those reported in Figure 3.6, indicating that 
complexation occurs through a similar pathway with respect to Gemini surfactants. In 
the SH14 case the counterions released are CF3COO-, which also give high SAXS 
contrast, due to the presence of fluorine atoms. 
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Figure 3.6: SAXS intensity diagrams of SH14 micelles, siRNA and complexes at two charge 
ratios (CR = 0.75 and CR = 1.25) recorded after 50 ms from mixing. The peak maxima were 
located at 1.38 nm-1 and 1.35 nm-1, corresponding to repeat distances of 4.65 nm and 4.58 
nm for CR = 0.75 and CR = 1.25, respectively. In the complex solution the total surfactant 
concentration (1.25x10-3 M) is approximately 3 times the CMC of SH14. In the reference 
systems siRNA is 4.5x10-5 M and SH14 is 1.25x10-3 M. 
 
 
Selected SAXS diagrams recorded for the siRNA/12-6-12 complex (CR = 0.75 
and surfactant concentration 1.25x10-3 M) are reported in Figure 3.6, as an 
example of time evolution. Two features common to all the investigated systems 
were the progressive increase of the intensity at very low q and of the quasi-
Second Part –Chapter3- 
 
 
65 
 
Bragg peak height, until a plateau was reached. This behavior indicated the size 
increase of scattering objects in solution and their progressive internal ordering, 
as discussed below.  
The evolution of the peak position was studied during 10-15 minutes from the instant of 
mixing. This is a typical time interval required to prepare complexes before use and for 
this reason it was chosen in our experiments. 
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Figure 3.6: Representative SAXS intensity diagrams of the siRNA/12-6-12 complex at CR = 
0.75 and surfactant concentration 1.25x10-3 M. in the time range 0.16-825 s after the mixing. 
The arrows indicate the increase of the very low q intensity and of the Bragg peak height at 
increasing time. 
 
 
The qmax trend for complexes prepared at CR = 0.75 and CR = 1.25 with different 
surfactants is reported in Figure 3.7. In all systems investigated the process of complex 
formation, revealed by the onset of measurable periodicity, took place in less than 50 
ms. This time scale agree with the one measured by stopped-flow circular dicroism in 
systems containing dimethyldioctadecyl ammonium bromide (DDBA), dendrimers, or 
1,2-dioleoyl-3-trimetthyammonium-propane (DOTAP) unilamellar liposomes and 4.9 
kbp DNA plasmid.113 50 ms or shorter is thus a time lapse during which cationic 
molecules or aggregates bind to nucleic acids, independently of their length and of their 
being DNA or RNA. The present study will thus access the stage of growth and 
reorganization of the complexes rather than their formation. 
The trend followed by the peak position qmax depended on surfactants, as shown in 
Figure 3.7. In fact qmax values got constant after 5 s for 12-12-12, decreased slowly for 
12-6-12 and 12-3-12 and increased slowly for SH14. However, all systems reached a 
plateau in 50-80 s, indicating that after this time lapse the composition of the repeat 
units did not change.  
The repeat distance depended on the surfactant involved in complexation and was in the 
order:  
 
SH14 > 12-3-12 > 12-6-12 > 12-12-12. 
 
The longer distance in the siRNA/SH14 systems was attributed to the 2 CH2- longer 
hydrocarbon chain of this surfactant, in agreement with previous SANS investigation.104 
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The difference observed in the siRNA/Gemini series followed the length of the spacer 
in the surfactant molecular structure and was attributed to a different hydration of the 
complex. The “bump” observed in the qmax time evolution of the siRNA/12-12-12 
system (Figure 3.7, lower panel) is a rearrangement reflecting the flexibility of these 
surfactant molecules.  
Interestingly, the same behavior was closely reproduced when both the concentration of 
surfactant and siRNA were halved, i.e. when complexes at the same CR were prepared 
from solution of micelles and siRNA twice more diluted (data not shown). The same 
bump was also observed at CR = 0.75, though in this case it was less intense, due to a 
smaller concentration of the complex below the neutrality point. These similarities 
indicate that complex formation followed reproducible path, at least in the experimental 
conditions of the present study. It is also worth noting that the low d values obtained for 
all systems indicate that strong squeezing of pre-existing micelles and siRNA occurs 
upon complex formation.  
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Figure 3.7: Time evolution of the quasi Bragg peak position in complexes prepared from different 
surfactants at the same concentration (1.25x10-3 M) at two different charge ratios. 
 
 
In the early stage (first few seconds), the evolution of Gemini complexes differed 
from SH14 complexes in that the repeat distance of the former systems increased, 
whereas SH14 complexes showed a slight internal shrinking (Figure 3.7). This 
was attributed to water intake and water expulsion, respectively, and was traced 
back to the higher charge density present on the Geminis’ polar head, which 
allows for more extended hydration. Water expulsion upon siRNA complexation 
with cationic PAMAM-dendrimers has been described as a relevant phenomenon 
by MD simulation although on a shorter time-scale (~10-9 s).114 
The width of Bragg peaks, usually expressed as Full Width at Half Maximum 
(FWHM), is another parameter which gives valuable information on the structure 
of complexes. In powder samples the FWHM is related to the mean size of 
crystallites through the Schrerrer relation115 and in soft condensed matter it is 
inversely proportional to the extension of the coherence domains from which this 
correlation originates.116,117 In our experimental conditions other broadening 
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factors, such as q-resolution, were much smaller than the measured widths and 
could be disregarded. 
For the siRNA/12-6-12 system, the FWHM value was 0.45 nm-1 and 0.37 nm-1 at CR = 
0.75 and 1.25, which correspond to coherence length (ξ = 2π/q) of 13.8 nm and 16.7 
nm, respectively. For the siRNA/SH14 system (Figure 3.8) FWHM was 0.41 (CR = 
0.75) and 0.46 (CR = 1.25), with corresponding ξ = 15.4 and ξ = 13.5, respectively. 
Coherence domains were modeled as made of “sandwiches” in which siRNA and 
micelles are alternately repeated. By assuming this layer arrangement, the average 
number 〈N〉 of sandwiches in the complex was evaluated, in analogy with SAXS studies 
performed on smectic systems.118 
 
〈〉 = ?& STUV⁄  
 
Figure 3.8 shows the time evolution of siRNA/12-6-12 and siRNA/SH14 systems 
(CR=1.25, two different concentration). The behavior of both surfactants was in 
agreement with an exponential growth of the number of correlated structural units. This 
suggests a first order kinetics in the ordering process. The complexes containing SH14 
were ordered on smaller length scale and their structure was almost unchanged at lower 
total surfactant concentration, while in the case of 12-6-12 a larger extent of correlation 
was observed for the more concentrated system. In fact, the final number of correlated 
layers (〈NX〉) was ~ 6 at [12-6-12] = 6.25x10-4 M and 7-8 at [12-6-12] = 1.25x10-3 M.  
The fact that GY and 〈〉 vary in the same way validates the interpretation of FWHM in 
terms of number of repeated structural units. The long time evolution was described by 
an exponential increase for all systems except the 12-12-12 complexes, which 
underwent the structural rearrangement mentioned above in the time window 50-150 s. 
Figure 3.8 reports the final number of layers 〈/〉 in complexes made by different 
surfactants at CR = 0.75 and CR = 1.25. 
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Figure 3.8: Time evolution of the number of correlated layers in siRNA/micelle complexes 
for surfactants 12-6-12 and SH14 at two different concentration and CR = 1.25. 
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To obtain information on the size of complexes I(q) data were analyzed at low q by 
using the Guinier approximation:119 
 
 = <	Z[\	−13 
	GY 
 
where I0 is the extrapolated  → 0 intercept and GY  is the gyration radius of the 
scattering objects, i.e. the average squared distance of individual scatterers from the centre 
of the aggregate. 
 
Surfactant Concentration, M CR <Nf> 
12-3-12 
6 25 10-4 
0.75 5 
1.25 5.4 
1.25 10-3 
0.75 4.6 
1.25 5.3 
12-6-12 
6.25 10-4 
0.75 6.4 
1.25 5.9 
1.25 10-3 
0.75 6.6 
1.25 7.5 
SH14 
6.25 10-4 
0.75 3.7 
1.25 3.2 
1.25 10-3 
0.75 3.5 
1.25 3.6 
 
Table 3.4: Average number of smectic layers in siRNA/micelles complexes (see text for details). 
 
 
Figure 3.9 shows the Guinier fitting for the system siRNA/12-6-12 at CR=0.75 and at 
surfactant concentration 1.25x10-3. In this system GY  grows from 11.58 nm, measured 
0.32 s after mixing, to 14.42 nm in about 800 s.  
The time evolution of GY  showed a rapid initial growth and an asymptotic trend, which 
was fitted by a stretched exponential. 
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Figure 3.9: Guinier fitting of the SAXS low q region for the siRNA/12-6-12 complex at 
CR=1.25 and [12-6-12]=1.25x10-3M. The obtained _` 	value are: 11.58±0.24 nm at 0.32 s; 
12±0.19 nm at 2.72 s; 13.06±0.16 nm at 22.89 s; 14.10±0.12 nm at 265.15 s; 14.42±0.14 nm at 
825.29 s. 
 
 
Noteworthy, a particular form of stretched exponential, the Avrami equation,120 is 
conventionally used to describe nucleation and growth processes (Figure 3.10).121,122 A 
stretched exponential behaviour was consistent with a broad set of characteristic times 
involved in complex formation,123-125 which could be accounted for considering micelle 
deformation, association of oppositely charged aggregates, re-ordering etc., as 
suggested by the quasi-Bragg peak analysis. At lower surfactant content, the succession 
of increasing and decreasing steps was more resolved, as shown in Figure 3.10. 
We can also notice that diluting twice the system has no marked effect either on the 
<Nf> or the GY  values. 
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Figure 3.10: Time evolution of _`  after mixing siRNA with surfactants 12-6-12 or SH14 at 
two different concentration and CR = 1.25. The continuous line are fitted with a Weibull 
function _` = a − b	c def , where a, b, d		and f are best fit parameters (f = h.hjk	and 
f = h. hll	for 12-6-12 and SH14, respectively). 
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Table 3.5 reports the values of GY  at the final state of siRNA/micelles nucleation. For 
Gemini complexes the higher values were obtained at CR = 1.25, regardless of 
surfactant concentration. Therefore, we hypothesize that siRNA content could be the 
factor limiting the aggregation process. For SH14, consistently with the results of peak 
analysis (Table 3.5), smaller variations with CR and surfactant concentration were 
found. 
 
Surfactants Concentration, M CR limit Rg, nm 
12-3-12 
6 25 10-4 
0.75 17.1 
1.25 19.8 
1.25 10-3 
0.75 14.6 
1.25 21.5 
12-6-12 
6.25 10-4 
0.75 7.3 
1.25 22.6 
1.25 10-3 
0.75 14.4 
1.25 23.1 
12-12-12 
6 25 10-4 
0.75 13.1 
1.25 24.4 
1.25 10-3 
0.75 15.2 
1.25 26.6 
SH14 
6.25 10-4 
0.75 16.6 
1.25 13.9 
1.25 10-3 
0.75 16.2 
1.25 15.7 
 
Table 3.5: Long time _` values for complexes made with different surfactant at two concentrations. 
 
 
The data extracted from Bragg peaks and Guiner analysis allowed drawing the 
scheme reported in Figure 3.11 to illustrate the process of complex formation. 
This scheme is also consistent with the mechanism proposed by Zhou et al. for 
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the complexation and time evolution of highly charged poly(amidoamine) 
(PAMAM) complexes with siRNA.126 
 
 
 
 
Figure 3.11: Sketch of the main steps involved in complex formation. 
 
 
We studied the kinetics of self-assembly in systems containing cationic micelles 
and siRNA by time-dependent synchrotron SAXS.127 These data refined and 
completed the structural investigation previously performed by Dynamic Light 
Scattering, Zeta Potential and SANS, which reported on the final state of 
complexes and were recorded during ~20 minutes after waiting another ~15 
minutes, following a common protocol used in biological trials. 
SAXS allowed following the structural evolution of complexes from few ms till 
10-15 minutes after mixing. These time resolved experiments revealed that 
counterions release and complex formation occurs within 50 ms, as indicated by 
marked increase of the scattering intensity at low q and at high q (quasi-Bragg 
peak). In the newly formed aggregates siRNA and micelles were alternately 
layered in “sandwiches” with repeat distance of 3-4 nm. Further rearrangement 
brought to larger coherence domains made by a compact array of 4-8 units. 
Aggregates containing SH14 were less ordered compared to Gemini surfactants. 
At low q, Guiner analysis gave information on the gyration radius of the 
complexes, which was in the range 7-27 nm. 
No larger aggregates (hundreds of nm) were detected up to 10-15 minutes from 
preparation. Since the transient states of complexes might be as relevant as the 
final state for their transfection efficiency we decided to get better inside in the 
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kinetic pathway of their formation. We are currently investigating complexation 
details by computational techniques to obtain finer insight on the siRNA/micelles 
complex structure. However, the obtained data are encouraging evidence in the 
perspective of using these systems in vitro or in vivo after preparation by simple 
mixing a micelle solution of the cationic surfactant and a siRNA solution, both of 
which are obtained without passing through irreversible steps, such as sonication 
or extrusion. 
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Chapter 4 
 
4.1 Material and methods 
4.1.1 Cell treatments.  
In order to investigate whether gemini surfactants and their complexes with siRNA have 
cytotoxic effects on cells in vitro, we selected three cell lines: Human Embryonic 
Kidney 293 (HEK293), Human Colon Carcinoma (HCT8) and Chinese Hamster Ovary 
(CHO). HEK 293, HCT8 and CHO were grown respectively in DMEM (Dulbecco’s 
Modified Eagle Medium), RPMI (Roswell Park Memorial Institute Medium) and 
DMEM-F12 (Dulbecco’s Modified Eagle Medium-F12), supplemented with 10% fetal 
bovine serum (FBS), 1% L-Glutamine and 1% (penicilin/streptomicine) antibiotics. 
Cells were incubated at 37°C in a 5% CO2 atmosphere. One day before treatment, 
1.5×104 cells per well were seeded with 500 µL of growth medium into a 24-well plate 
for 24h.  
Three different gemini surfactants (12-3-12, 12-6-12 and 12-12-12) were added to 
culture medium containing 10% serum at the final concentration of 10-4 M, 5x10-5 M, 
10-5 M and 5x10-6 M. 
We also tested the cytotoxicity of the complexes formed by Gemini surfactants and 
siRNA. All experiments were carried out combining equal volume of Gemini and 
diluted solution of siRNA in order to obtain aggregates of charge ratio (N/P) 0,25. Then 
complexes were added in medium with 10% serum to obtain the follow concentrations 
of Gemini: 10-4 M, 5x10-5 M, 10-5 M and 5x10-6 M for 24h. All experiments were 
performed at least in duplicate. 
 
4.1.2 Cytoxicity Assay  
To quantify the cytotoxicity effect, cells were stained with propidium iodide (PI) 
(P4170 Sigma Aldrich), PI is a fluorescent dye that binds to double-stranded DNA. It 
can penetrate the compromised cell membranes but remains excluded from viable cells. 
The fluorescence in the cells was detected by flow cytometry using a FACSanto 
cytometer (Becton Dickinson) equipped with a 488nm argon laser and a 695/40 nm 
band-pass filter. After gemini surfactant treatments, cells of each sample were harvested 
and resuspended in 500 µL phosphate buffered saline (PBS). Prior to the flow 
cytometric analysis, 5 µL of stock solution (10mg/mL) of PI diluted 1:400 in PBS was 
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added to each sample. Samples were incubated for 1 minute on ice. A total of 10.000 
cells for each sample were analyzed, aggregates and debris were excluded. The 
percentage of PI positive cells were recorded.  
To compare the effect of the three gemini surfactants in the different cell lines, we 
normalized the value of PI stained cells treated with gemini surfactants and the 
complexes (CR=0,25) by the PI stained cells of untreated controls of each cell line.  
 
4.2 Results and discussion. 
The cytometric analysis showed a different sensitivity of cells in function of gemini 
surfactants concentration. The two higher concentrations (10-4 and 5x10-5 M) of gemini 
surfactants were very toxic and caused the death of all the cells. On the contrary the two 
more diluted solution were far less toxic to cells. This trend was observed for all the 
three cell lines treated with gemini surfactants alone and also associated with siRNA 
(Figure 4.1 and Figure 4.2). 
The HCT8 cell lines had the higher sensitivity among the three cell lines tested to 
gemini surfactants at 10-5 M concentration. Similar results were obtain treated this cell 
line with complexes diluted in medium in order to obtain 10-5 M of Gemini. 
The overall gemini surfactants citotoxicity effect seems to be proportional to the linker 
length at the concentration of 10-5 M  but at the lower concentrations (5 10-6 M) the 
toxicity seems inversely proportional to the linker length. These results suggest a 
complex combinatorial effect of gemini surfactants concentration, cell lines and linker 
length of gemini surfactants that generate a different level of toxicity in relation to 
different experimental setting. 
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Figure 4.1: Cytotoxicity effects of  three different gemini surfactant (12-3-12, 12-6-12 and 12-12-12) 
at 10-5 M and 5x10-6 M concentrations on HEK 293, HCT8 and CHO cell lines by flow cytometry 
analysis after staining cells with propidium iodide (PI). Values (± SEM) were normalized by PI 
stained cells of untreated controls. 
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Moreover citotoxic effect didn’t change with the adding of siRNA, indeed toxicity of 
the complexes depends only on the type of vector. There were no peculiar differences 
between the effect caused by gemini surfactants alone and their aggregates with siRNA. 
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Figure 4.2: Citotoxicity effects of complexes formed by three different Gemini and siRNA(CR=0,25) 
on HEK 293, HCT8 and CHO cell lines. These complexes were diluted in medium with 10% of 
serum in order to have the follow concentrations of surfactants 10-5M and 5x10-6M. Citotoxicity 
effect was measured by flow cytometry analysis after staining cells with propidium iodide (PI). 
Values (± SEM) were normalized by PI stained cells of untreated controls. 
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General conclusion 
 
Leukemia represents an heterogeneous group of malignancies with great variability in 
clinical course and response to therapy. Despite numerous advances obtained in the 
understanding the genetic and molecular basis of the pathology, a subset of patients 
remain refractory to conventional therapy. 
Nowadays the advent of the new “omics” like genomic, proteomic, metabolomic opens 
the possibility to make a molecular profile of cancer for each patient, in order to develop 
a personalized therapy. This molecular profile would allow to identify genes or proteins 
involved in the pathogenesis as possible biomarkers for a specific therapy. 
In recent years the involvement of potassium channel, and in particular hERG channel, 
in tumor biology has been demonstrated in our laboratory. It is well established that 
hERG exerts a relevant role in leukemia where it regulate cell migration and 
transendothelial invasiveness in acute myeloid leukemia. hERG is activated in the 
presence of bone marrow microenvironment, inducing chemoresistance in acute 
lymphoblastic leukemia. 
These experimental evidences suggest that hERG is a possible target in antineoplastic 
therapy and that hERG inhibitors can function as anticancer drugs. 
In this thesis we present a pharmacological approach to reduce the activity of 
overexpressed hERG channel avoiding side effects like QT long syndrome and 
arrhythmia and we propose innovative carriers for anti-hERG siRNA as possible 
molecular therapy. 
For the pharmacological effect we selected clarithromycin, a commercially used 
antibiotic. Experimental evidences demonstrate that it is a growth inhibitor and an 
antiangiogenetic agent of certain cancer cells. Therefore it was demonstrated that 
clarithromycin induces the inhibition of the late stage of autophagy, a mechanism of 
chemioresistance. In fact, the use of this drug restore the sensitivity to chemotherapy in 
chronic myeloid leukemia. 
In addition, clarithromycin reduces the activity of hERG channel in HEK293 stably 
transfected with hERG and FLG29.1 (ALL) where hERG is abundantly expressed.  
These characteristics, linked with known anthyarritmic effect, suggest the use of 
clarithromycin for leukemia treatment.  
Initially we tested the effect of clarithromycin on an acute promyelocitic cell line 
(HL60) where hERG is overexpressed, with or without bone marrow mesenchymal cell 
line (MSCs). It was possible to individuate the LD50 of clarithromycin for HL60 in 
suspension (37±5µM) and in co-colture (67±5µM). As expected, the effect of 
clarithromycin is larger for HL60 in suspension than in co-colture which underlines the 
protecting effect mediated by bone marrow microenvironment.  
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In a subsequent set of experiments we tested the effect of clarithromycin in combination 
with cytarabine, following the method of Chou-Talay in order to use the software 
Calcusyn. We tested this two drugs at their corresponding LD50, 37µM for 
clarithromycin and 45nM for cytarabine. This experiments demonstrate that the addition 
of clarithromycin to cytarabine reduce the chemoprotective effect induce by the 
presence of MSCs (CI=0.657). 
The encouraging data obtained from in vitro experiments led to in vivo experiments on 
SCID mice, injected with HL60 cell, tagged with luciferase. These experiments were 
performed by Dott.ssa Marika Masselli. In the first set of experiments it was 
demonstrated the capability of clarithromycin to block tumor development and 
invasiveness. In turn, this second set of experiments demonstrated the synergic effect of 
cytarabine in addition with clarithromycin. The efficacy of this therapy is evidenced by 
the long survival of the animal group where three are still alive (up to 200 days). 
We also explore the possibility of a molecular approach to hERG silencing by 
developing a new lipid based vectors for RNA interference (RNAi) targeting hERG. 
RNAi is a specific post-transcriptional silencing mechanism induced by small 
interfering RNA (siRNA) of 21pb. This phenomenon can be exploited for the treatment 
of diseases in which an overexpressed gene is involved. Despite this potentiality siRNA 
based therapeutics have not displayed major success so far and still present some 
physiological problems. The main barriers have been: (i) inefficient delivery to the 
correct cells or tissues, (ii) suboptimal gene silencing activity owing to instability and 
poor bioavailability of RNAi agents and (iii) toxicity due to off-target effects or immune 
activation. One of the main improvements is therefore expected by designing a delivery 
agents able to vehiculate siRNA to the target cells. For this reason we selected three 
Gemini surfactants:12-3-12, 12-6-12 , 12-12-12 and a triazine based surfactants SH14, 
as possible delivery agents of siRNA. In aqueous media these surfactants self-aggregate 
into spherical micelles and complex siRNA molecules through electrostatic interactions. 
We studied the physico-chemical properties of the complexes by time resolved SAXS at 
ESRF (Grenoble, France). These experiments allowed to elucidate the structural 
evolution of complexes from few ms till 10-15min after mixing. It was found that 
complex formation occurs rapidly (< 50 ms), the process being driven by counterion 
expulsion from the water-micelle interface. In the following instants siRNA and 
cationic micelles aggregate into “sandwiches” with repeat distance of 3-4nm and more 
structured assemblies appears, until a steady state is reached after 10-15 min. The final 
number of layer within the complexes is of 4-8units. 
Complexes obtained with SH14 are less ordered than those formed by Gemini 
surfactants. In all cases an estimation of the complex size, i.e. its gyration radius, give 
values in the range 7-27nm.  
We tested the cytotoxicity of Gemini surfactant and their complexes (CR=0.25) in three 
cell lines: HEK293, HCT8 and CHO. The two higher concentrations (10-4 M and      
5x10-5) were found to be toxic while the two more diluted solutions were acceptably 
safe toward cells. This trend was observed for all the three cell lines treated with gemini 
surfactants alone and in combination with siRNA. We could therefore identify a range 
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of concentration in which our newly designed systems can be used for transfection 
experiments. 
In this thesis the major intent was to increase the knowledge about hERG channel role 
in tumor in order to exploit these new informations for designing innovative anticancer 
therapies. 
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